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Abstract 
 
 
Prostate cancer (PCa) is the single most prevalent cancer in US men. PCa diagnosis and 
prognosis are crucial processes in managing patients and disease. These greatly affect decision-
making of treatment and post-treatment strategies. Manual histologic assessment of stained tissue 
forms gold standard of diagnosis and limits speed and accuracy in clinical practice and research 
of prostate cancer diagnosis. Outcome prediction by clinical, pathologic, imaging and 
computational tools outperforms manual ad hoc decisions, but the deficiencies in these tools are 
apparent and hamper effective and efficient treatment plans. Here, we sought to develop 
automated tools for cancer pathology using fourier transform infrared (FT-IR) spectroscopy 
imaging. We employ tissue microarrays (TMAs) to record IR imaging data and adopt elaborated 
computational and analytical algorithms and statistical methods to recognize patterns and to 
construct robust systems. We firstly suggest a statistical framework to examine FT-IR imaging 
from a large population data in appreciation of its design and to identify primary sources of 
variation. Secondly, we develop cancer detection method by combining FT-IR imaging with 
microcopy imaging. Extracted morphologic features are excellent in recognizing cancer tissue 
and robust to staining conditions. Thirdly, a novel decision-support system to aid cancer 
pathology is introduced and provides an easy access and maintenance of tissues. Lastly, we 
develop a new prognostic model utilizing FT-IR imaging where stromal chemical features are 
detected and utilized to characterize cancer progression. The computational and automated 
methods developed here will prove the utility of FT-IR imaging in cancer pathology and help the 
development of solid protocols for clinical translation, thereby advancing PCa pathology service 
today.  
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Chapter 1  
Introduction 
 
 
Prostate cancer (PCa) is the single most prevalent cancer in US men, accounting for one-third of 
non-skin cancer diagnoses every year, and is the second leading cause of deaths from cancer 
following lung cancer in US men [1]. PCa screening, including prostate-specific antigen (PSA) 
blood test and digital rectal exam (DRE), for the disease is widespread and attempts to identify 
cancer in asymptomatic individuals, but their accuracy and benefits for routine use remains 
controversial [2] [3]. The only definite diagnostic test available for PCa is manually-conducted 
histologic assessment of tissue upon a biopsy [4], where a small piece of prostate tissue is 
detached and examined microscopically. For almost a million cases a year [5-7] , a biopsy is 
conducted to detect or rule out cancer [6]. Once diagnosed with PCa, a few treatment options – 
radical prostatectomy (RP), radiotherapy, and hormonal therapy – are available for a patient. 
Receiving the treatments, a success rate of >65% has been reported with long-term follow-up [8-
10]. Early detection of tumor enables care providers to provide an appropriate treatment which, 
in turn, leads to high cure rates. Further, decision-making of treatment planning and post-
treatment strategies is critical for patient care, and precise outcome prediction is essential for the 
process. The pathology services will, hence, greatly benefit from accurate prediction of clinical 
outcome as well as precise detection of PCa.  
1.1 Optical Microscopy and Current Prostate Pathology 
Prostate tissue is structurally complex, in which epithelial cells line glandular ducts and 
heterogeneous stroma surround them. Stroma typically contains fibroblasts, smooth muscle cells, 
collagenous extra-cellular matrix, blood vessels, blood, nerves, ganglion cells, lymphocytes and 
other immune response cells as well as stones. Since the tissue does not have appreciable 
contrast in optical brightfield microscopy (Figure 1.1a), tissue samples are commonly stained 
using hematoxylin and eosin (H&E) prior to review by a pathologist. The stain is specific in 
2 
 
limited terms – staining protein-rich regions pink and nucleic acid rich regions of the tissue blue 
(Figure 1.1b). A pathologist is trained to recognize, from a stained tissue sample, the morphology 
and local architecture of glands as well as their structural alterations that indicate disease. The 
specific cell type that is used to recognize glandular structures is the epithelial sub-type. In 
prostatic carcinoma, which comprises more than 95% of prostate cancers [4], the cells of interest 
are epithelial cells [11]. Epithelial cells line 3D ducts in intact tissue and, hence, appear as cells 
lining empty circular regions (lumens) in images of histologic sections. Patterns of distortions of 
lumen appearance and spacing, as well as the arrangement of epithelial cells relative to lumens, 
have been characterized to indicate cancer and characterize its severity (Gleason grade) [12, 13]. 
The greater the distortion and loss of regular structure, the worse (higher grade) the cancer. 
While the specific causes of PCa remain unknown [14], epithelial transformations characterize 
PCa at all stages. 
Recognizing structural distortions indicative of disease is a manual pattern recognition 
process that matches patterns in the tissue sample to standard patterns. Manual examination is 
powerful in that humans can recognize disease from a wide spectrum of normal and disease 
states, can overcome confounding artifacts, detect unusual cases and even recognize deficiencies 
in diagnoses. Manual examination, unfortunately, is time-consuming, expensive, and leads 
routinely to variability in grading disease [12]. It is well known that the grading of prostate 
tissues suffers from intra- and inter-pathologist variability [15]. In studies of intra- and inter-
pathologist reproducibility [16] [17], exact intra-pathologist agreement was achieved in 43-78% 
of the instances, while exact inter-pathologist agreement was observed in 36-81% of the 
instances. It is also known that the variability of the grading can be reduced after pathologists are 
re-trained. There could be many ways to educate pathologists such as meetings, courses, online 
tutorials, and etc [18], but these are not time- and cost-effective for routine everyday decisions. 
Computer-aided recognition of disease samples and grade patterns [19] therefore holds the 
potential for more accurate, reproducible and automated diagnoses [20, 21]. Unfortunately, tissue 
samples stain variably in populations due to biological diversity, with variations in stain 
composition, processing conditions and histotechnologists. The net result confounds automated 
image analysis and human-competitive recognition of cancer has not been automated for routine 
use. A robust means of automatically detecting epithelium and correlating its spatial patterns to 
determining cancer presence is highly desirable but yet unsolved. 
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Going beyond problems of diagnosis, the selection of proper treatment option and post-
treatment strategy is also a complicated and crucial process in managing patient and disease, and 
is dependent on several factors including the benefits and side effects of treatment, life 
expectancy, and comorbidities [22]. Different treatment options may be incompatible; for 
example, conducting RP is very challenging after a patient has undergone radiation therapy [23], 
and its effects may not be identical for different patients. Also, patients who are poorly informed 
about outcome likelihoods are more likely to be dissatisfied with a (failed) treatment. 
Conventionally, clinicians have made the outcome prediction, but their capability of providing 
accurate predictions is limited [24]. As alternatives, various types of prediction tools have been 
recently developed and already outperformed clinicians [24] [25] [26]; among many tools, 
Kattan nomograms [27] [28], graphical tools incorporating several clinical predictors such as 
PSA level, Gleason grade, and pathologic stages, and CAPRA-S score [29], assigning relative 
scores for the clinical variables, are widespread and considered as the most accurate tools for 
predicting outcomes after RP. Despite the success of such tools, they are deficient in several 
ways; for example, the outcome prediction among intermediate and high risk patients is more 
complicated [30] [31], a tendency to overestimate likelihood of risk-free survival, especially for 
the patients at lower risk, has been reported [32], and sub-stratification of low-risk patients has 
been suggested [33]. Incorporating additional clinical information has not significantly improved 
the current tools [34] [35]. Hence, alternate manners of analyzing disease and obtaining efficient 
and effective information beyond those currently available are in demand. Herein, integrating 
with novel biomarkers and imaging tools may hold a potential to improve the outcome prediction 
[22]. 
A major roadblock in advancing the current practice of cancer pathology has been the limited 
information present in the collected data. For example, different cell types and morphologies are 
identified by recognizing colors that are distinctive of empty space (usually close to white), 
apical portion of epithelial cells (usually pink) and the basal layer of epithelial cells (usually 
pink-dark blue), but color conditions are unsteady. Clinical information such as Gleason grade, 
age at surgery, and pathologic stages, on which the current outcome prediction tools rely, can be 
utilized to predict disease outcome, but their failures are apparent as described above. 
Immunohistochemical probes add useful information to diagnostic and prognostic processes and 
are effective in understanding specific aspects of the disease, e.g. loss of basement membrane 
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and increase in the expression level of tumor-related antigens. For routine diagnostic and 
prognostic pathology, however, the use of such molecular stains is expensive, time-consuming 
and does not actually address the need for an operator-free method. On the other hand, additional 
molecular data is now available using label-free spectroscopic imaging, also known as chemical 
imaging [36].   
1.2  Chemical Imaging 
Fourier transform infrared (FT-IR) spectroscopic imaging provides non-perturbing imaging by 
combining the spatial specificity of optical microscopy with the molecular selectivity of 
vibrational spectroscopy. Mid-IR spectral frequencies are resonant with the fundamental 
vibrational mode frequencies in molecules; hence, the IR absorption spectrum at each pixel is a 
quantitative record of composition [37]. FT-IR imaging has been successfully applied to various 
biological and biomedical problems such as determining molecular concentrations [38, 39] and 
structure [40, 41], characterizing cell components [42] and cancer diagnosis [43-45]. While FT-
IR imaging provides useful and objective information, its relationship to the existing clinical 
practice of using H&E stained tissue is not yet clear. Integrating FT-IR imaging with the 
conventional techniques will benefit both communities and help to improve the medical care in 
urology. There are, however, no reports of practical protocols that have been translated to 
clinical use. In particular, there is little evidence yet that FT-IR imaging can add useful 
information or protocols that improve current clinical practice beyond conventional pathologic 
examinations.   
Translating the findings from FT-IR imaging and its analysis to the clinical practice requires 
assuring its validity, accuracy and reliability, which, in turn, necessitates a sophisticated and 
careful quality control on every aspect of FT-IR imaging and the analysis. To achieve this, a 
thorough understanding of the technology and data is a priority. Most biomedical samples are 
chemically complex, and their analysis often relies on treating the spectrum as a characteristic 
signature of the identity and/or physiologic state of the sample. Many studies seek to find the 
unique spectral signature or differences in spectral signatures between given classes of samples 
from a statistical, rather than purely biochemical, perspective. These classes may be tissues with 
different grades of disease or different cell types within the same tissue type, for example. 
Finding an IR imaging-based approach that can distinguish between disease states is of 
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tremendous technological and medical importance as it can potentially improve diagnostic 
information, reduce costs and prevent errors. The tasks in this approach would be to discover 
differences in spectral properties of classes and develop a computer algorithm such that every 
spectrum (pixel) can be classified into a particular class without using dyes, stains or human 
supervision. [46] Though conceptually straightforward, this approach is exceptionally 
challenging not only because of the subtle differences between various components and disease 
states in tissue but also because of the variation in IR spectra that obscures differences between 
disease states. This analytical variation may overwhelm differences due to disease states and is a 
prime cause of the failure of many analytical methods in providing robust diagnostic protocols. 
The question of analytic variability remains to be resolved and is a topic of much interest in IR 
spectroscopy[47] and other analytical technologies. [48],[49],[50] 
1.3  Thesis Statement 
There are limitations imposed on the current prostate pathology due to manual and subject 
decision-making and shortcomings of available tools. Alternative, high-throughput, and objective 
means to alleviate or overcome such constraints are in demand, and imaging techniques are 
promising tools for improving and complementing the prostate pathology. Much effort has been 
made to improve and develop automated tools for this purpose, but the impact of such work on 
current clinical practice has been relatively small. In this thesis, we seek to fulfill the unmet 
demands through FT-IR imaging in appreciation of the limits of current prostate pathology. We 
not only take advantage of FT-IR imaging but also bridge the gap between FT-IR imaging and 
the conventional pathologic methods.  
The major contributions of this thesis include: 1) we prove the utility of FT-IR imaging in 
prostate pathology, and 2) we provide a statistical framework for the development of protocols 
for clinical translation. Demonstrating the usefulness of FT-IR imaging, we achieve an effective 
fusion of the complementary information from two different modalities, namely optical 
microscopy and IR spectroscopy, and develop a novel decision-support system that can greatly 
help the diagnostic process as well as a new predictive tool for prostate recurrence. Developing 
the statistical framework, we facilitate comprehensive and thorough understanding of the image 
or data and provide guidelines to design statistically valid studies using spectroscopic imaging. 
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On completion of the studies, we will present the systematic protocols which couple FT-IR 
imaging with elaborated computational, analytical algorithms and methods. The protocols will 
facilitate the effective and efficient quality development, maintenance, and improvement of 
clinical services, that is to achieve the end goal of advancing the prostate pathology today.  
1.4  Figures 
 
Figure 1.1: Staining allows visualization of tissue features. (a) an unstained image has little 
contrast while (b) the application of H&E stain highlights nucleic acid-rich regions as blue and 
protein-rich regions at pink. (c) structure of a prostate gland. It is notable that the stain is 
universal in that it is not diagnostic of cell type or disease. The stain serves only to provide 
contrast that is subsequently used by a human to recognize cell types and diagnose disease. Black 
scale bars represent 500 . 
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Chapter 2  
Background 
 
 
2.1 Fourier Transform Infrared (FT-IR) Spectroscopy Imaging 
Infrared (IR) spectroscopy is a chemical analytical technique, which measures vibrational 
characteristics of chemical compounds in a sample. As an IR radiation passes through a sample, 
the chemical bonds, in the sample, will stretch, contract or bend, and a specific range of 
frequencies (or wavenumbers) in the IR radiation tends to be absorbed by a particular chemical 
compound. The frequencies, that are absorbed by the chemical compound, are matched with the 
fundamental vibrational mode frequencies in molecules [37], and are consistent regardless of 
changes in temperature, pressure, and the structure of the rest of the molecule. Accordingly, the 
IR spectrum could uniquely identify a sample, and IR spectroscopy could be an excellent tool for 
quantitative analysis. Recently, it has been demonstrated that the IR spectra coupled with 
numerical computation could yield an accurate and reproducible method for large patient 
populations [51]. Nearly sixty year ago, an attempt to characterize a tissue sample with IR 
spectroscopy was made [52], but issues with instrumentation hindered its wide application to 
various fields and materials. In an earlier instrumentation, only a single spectrum was obtained 
from a sample, and the spectrum was recorded by changing wavenumbers over time, i.e., the 
absorption of an IR radiation with one wavenumber was measured one at a time. As a result, it 
was not until FT-IR imaging was developed and finer spatial resolution was obtained that a 
practical instrument became available [53]. FT-IR technique simultaneously collects the 
absorption spectra in a wide range of IR frequencies by coupling microscopy and interferometry 
into an integrated instrument [54]. A light source emits a beam containing the full spectrum of 
frequencies to be measured, and a Michelson interferometer modifies the combinations of 
frequencies. Different combinations result in new data points (raw data). Converting the raw data 
into the desired format, which is the absorption of an IR radiation for each wavenumber, has 
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been mathematically shown to be a Fourier transform of the raw data [54]. Development of the 
focal plane array detector [55], consisting of many small and individual detectors laid out in a 
grid pattern, and the implementation of rapid-scan imaging [56] coupled with FT-IR also 
enhanced data quality and acquisition speed.  
2.1.1 Data Pre-processing 
In FT-IR imaging, each pixel yields a spectrum. Different frequencies are related to different 
chemical compounds or properties, but some or many of them may be uncorrelated or redundant. 
Also, not all the frequencies are informative; for example, the spectral ranges corresponding to 
water vapor or atmospheric carbon dioxide clearly are irrelevant to an understanding of tissue 
structure [57]. Further, the common problem of high-dimensional data, namely “curse of 
dimensionality”, makes difficult to extract pertinent information from it. With all of these 
concerns and difficulties, it is necessary to reduce the dimensionality to a manageable smaller 
size that still represents the intrinsic and essential characteristics of image or data. In order to 
reduce the dimensionality without loss of efficiency, spectral metrics are defined by 
spectroscopists. The spectral metrics can be the spectral absorbance at a peak position, ratio 
between two peaks, or area and center of gravity of a spectral region [46] [57]. A set of spectral 
metrics, defined in this way, preserves the intrinsic biochemical properties of the sample under 
consideration and serves as the initial feature space for the (classification) model in further 
analysis. A subset of the spectral metrics may be selected to maximize the performance of the 
model, e.g., a subset of the metrics to maximize the distinction between epithelium and stroma.  
2.1.2 Histologic Segmentation 
Among various biomedical applications and problems, histologic segmentation has been 
successfully conducted [51] by using FT-IR imaging (Figure 2.1). Initially, 93 spectral metrics 
(Table A.1.7) were defined and computed for different histologic classes such as epithelium, 
stroma, muscle, stone, lymphocytes, and blood. A Bayesian classifier was trained and optimized 
with respect to the classification performance, which is measured by area under the curve (AUC) 
for the receiver operating characteristic (ROC) curve. Finally, 18 spectral metrics were selected 
and >0.9 AUC was achieved for the most cell type classification [46, 57]. The approach has been 
9 
 
extensively validated in providing histologic recognition using tissue samples from over 1000 
patients and tens of millions of pixels using tissue microarrays (TMAs).  
2.2 Analysis of Variance (ANOVA) 
ANOVA is a statistical model for partitioning the total variance of the measured quantity in an 
experiment into various identifiable sources of variation. Application of this model begins with 
identification of experiment-associated factors that are potential sources of variation. Using 
ANOVA, we can test if the differences between groups (called “levels”) [58] determined by a 
factor are significant, and estimate the variance attributable to the factor. The effect of the factors 
can be either “fixed” or “random”. Random factors are assumed to have the infinite levels, and 
the levels in the experiment represent random samples from a large population. The levels of the 
fixed factors are finite and comprise the population of interest in the experiment. Histologic class 
and subcellular components are fixed effects and array, patient, and core are random effects. An 
ANOVA model containing only fixed effects is designated as a fixed effect model, and a random 
effect model comprises of random effects. When both fixed and random effects present, the 
model is called as a mixed effect model.  
The effect of the factors and their true variances can be estimated by computing an ANOVA 
table and applying expected mean squared method equating the observed and expected mean 
squares [58]. Consider a TMA consisting of tissue samples from several patients, where n 
samples were taken from each patient. An IR absorbance of one wavenumber was measured for 
each sample, i.e., n measurements were made for each patient. Here, patient is the only factor, 
and the difference between patients in terms of IR absorbance is of interest. In this setting, an IR 
absorbance can be expressed as y =  + 	 + 
  where y  is IR absorbance of kth sample 
from jth patient,  is overall mean, 	 is patient effect (j = 1, … , ), and 
  is residual error effect. 
The total variance can be partitioned into two parts;  =  +  where  and  indicate 
the variance of patient effect and residual effect, respectively. Partitioning of variance can be 
carried out by computing sum of squares (SS) and  mean squares (MS).  
SS = SS + SS  = ! "#$ − & + ! "# − #$&

,
 
where SS, SS, and SS   denote total SS, patient SS and residual SS, respectively. 
#$ represents jth patient mean. MS of a factor is calculated as dividing SS of the factor by its 
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degrees of freedom (df). And, expected mean squares (EMS) of the two factors are expressed as 
follows: 
EMS =  +  
EMS  =   
Now, variances can be estimated by equating MS and EMS of the factors. Dividing the estimated 
variance by the total variance provides the portion of explained variance by each factor. We note 
that there are alternative methods to estimate variance components, for instance, maximum 
likelihood estimation, restricted maximum likelihood estimation, and minimum norm quadratic 
unbiased estimation. These alternate approaches do not suffer from negative variance 
problem[58]. In the ANOVA model, more factors can be included such as histologic class *. 
Further, there could be an interaction between two factors (interaction effect) if the effect of one 
factor differs over different levels of the other factor. Both 	  and * are designated as main effect, 
which is the effect of a factor averaged across the levels of other factors.  
For a mixed effects model, variance components can be computed in two ways – one is to 
compute variance components only for the random factors, and the other is to calculate them for 
all the factors regardless of where they are fixed or random[58]. The former is the more correct 
approach, and the latter is arguable, but it provides a useful interpretative tool. In fact, in terms of 
expected mean squared method, calculating the variance components for fixed and random 
factors is equivalent. However, the interpretation is very different. The estimated variance for a 
fixed factor is the variance between the means of the particular levels only for the population 
under consideration in the experiment, but the variance component for a random factor is the 
estimate of the variance between the means of all possible levels that could have been used in the 
experiment. In this study, we compute variance components for both fixed and random factors 
since the variation introduced by the fixed effect (histologic class and subcellular component) is 
of our interest. 
Conducting a hypothesis test, F-test, we can assess if the group means significantly differ. 
The null hypothesis can be stated as either no difference between group means exists (fixed 
effect) or the variance between all groups equals to zero (random effect). The significance of the 
null hypothesis can be tested by computing F-test statistic, which is the ratio of two mean 
squares: between-group and within-group variances. For example, testing the statistical 
significance of histologic class effect in between-histologic class model, F-test statistic is the 
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ratio of the mean square of histologic class effect and the means square of the interaction effect 
of histologic class and array, which measures the variation of histologic class relative to the 
variation of the interaction between histologic class and array (Table A.1.2). P-value for the F-
test statistic can be calculated by comparing it to the F-distribution with between-group and 
within-group df. The lower p-value denotes that the difference in the group means is statistically 
significant. Note that statistical significance is sensitive to the sample size, i.e., df. Much larger 
sample size compared to the number of groups could lead to the significant p-value regardless of 
the magnitude of group mean differences. 
2.3 Classification 
2.3.1 Support Vector Machine (SVM) 
Given a training dataset +,-, #./012  with a feature vector - ∈ ℛ  and a (class) label # ∈
+−1, +1/, SVM [59] constructs a separating hyperplane which aims at maximizing the margin 
between two classes. Constructing the hyperplane is equivalent to minimizing the structural risk 
function given by 
V,6, 7, 8. = 12 6
:6 + C ! 8

01
 
subject to: #<6- + 7= ≥ 1 − 8 and 8 > 0, A = 1, … ,  
where C is a parameter controlling tradeoff between training error and model complexity, # is a 
class label, 8 is slack variable, and n is the number of training examples. It is known that the 
dual representation of the above problem is easier to solve and given by  
minimize: B,C. = − ∑ C01 + 1 ∑ ∑ ##CC"- ⋅ -&0101  
subject to: ∑ #C01  and 0 ≤ C ≤ G, A = 1, … ,  
where C is a Lagrange multiplier. SVM was originally proposed as a linear classifier, but it can 
also be a non-linear classifier if we replace the inner-products ,- ⋅ -. by a kernel function 
K"- , -& . Some popular kernel functions include: 1) polynomial kernel K"- , -& =
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"- ⋅ -&, I > 1  2) radial basis kernel K"- , -& = exp M−NO- − -OP , N > 0	  3) simoid 
tangent K"- , -& = tanh"U- ⋅ - − V&, U > 0	and	V > 0. An imbalance of positive and negative 
samples in training data may cause the hyperplane computed by SVM to be biased toward either 
of two classes. To deal with this problem, different cost factors GX and GY are often introduced in 
the structural risk function to adjust the cost of false positives and false negatives, and the 
problem becomes [60] 
V,6, 7, 8. = 126:6 + CX ! 8

:[\01
+ CY ! 8

:[]01
 
subject to: #<6- + 7= ≥ 1 − 8 and 8 > 0, A = 1,… ,  
The ratio between two cost functions was chosen as  
CXCY =
number of negative training examples
number of positive training examples  
to make the potential total cost of the false positives and the false negatives the same. 
2.3.2 Ranking-SVM 
Whereas SVM learns a separating hyperplane that maximizes the margin between support 
vectors representing different classes, Ranking SVM [61] seeks to learn a function ^ ∈ F 
satisfying the following relations for any pair of data points:  
# > # ⟺ ^,-. > ^"-& 
where a label # denotes an ordering preference or a rank and a complete ranking can be made 
among the labels, e.g., #2 ≻ #2Y1 ≻ ⋯ ≻ #1 where ≻ represents an order preference.  
Constructing such function can be formulated as follows: 
mine,f\]gh
1
26:6 +
G
|j| ! 8,,.∈k
 
s.t. ∀,A, m. ∈ j:	6:"- − -& ≥ 1 − 8 
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where C is a tradeoff between training error, P is a set of preference pairs, and model complexity 
and 8  is a slack variable. Intuitively, the function aims at minimizing the number of swapped 
pairs of training data points in terms of their desired rankings [61]. Interestingly, optimizing the 
formula is, in fact, equivalent to that of a classification SVM except that pairwise difference 
vectors "- − -& are provided. 
2.4 Feature Selection 
Feature selection is a procedure to select a subset of relevant features from all available features. 
This selection is generally based on the criterion of high performance of the classification model 
on a training dataset, but also strives to ensure generalizability beyond that dataset. It gains more 
attention due to the prevalence of high-dimensional data. The presence of (many) irrelevant 
features may incur substantial costs in terms of computational time and space, lead to over-fitting, 
and reduce the classification model performance. In other words, selecting a subset of relevant 
features can achieve efficient and effective model construction as well as improved visualization 
and understanding of data. However, we note that feature selection itself can burden the model 
construction since it often requires exploring a huge feature space. Nevertheless, if done properly, 
its advantages are obvious.  
Numerous feature selection methods have introduced, and these can be grouped into three 
types: 1) filter method 2) wrapper method 3) embedded method. Filter method measures the 
goodness of the features from the data regardless of the classification model. In general, a score 
is assigned to each feature and lower scoring features are ignored for the further consideration. It 
is fast and simple, but the relationship between the selected features and the classification model 
is totally ignored. In wrapper method, the classification model is used as a black box [62]. This 
method searches for a good combination of features by evaluating the performance of the 
classification model on the data. As opposed to filter method, it can assess the interaction 
between the classification model and the selected features and the dependencies among features, 
but the search space grows exponentially with the number of features [63]. In embedded method, 
the feature selection scheme is incorporated into the model construction. It is efficient in terms of 
the model construction and comprehensive due to its consideration of both the model and 
features together [64]. 
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In this thesis, we adopt a two-stage feature selection approach where filter and wrapper 
approaches are combined. In the first stage, we apply filter approach where the relevance of 
features is assessed and irrelevant features are eliminated. Ordering them by the relevance, we 
compute the classification model performance for the set of i top-ranked features as varying 
values of i. The feature subset with the best performance is chosen as the Ccandidate, which is a set 
of features that is expected to be close to the optimal feature set for a dataset and a classification 
model under consideration. To measure the relevance and rank the features by the relevance, we 
adopt minimum-redundancy-maximal-relevance (mRMR), Log-odds ratio test, and Wilcoxon 
rank-sum test.  In the second stage, we adopt wrapper approach. Feature selection continues with 
Ccandidate as the starting point and searches for the optimal feature set, using the sequential 
floating forward selection (SFFS) method [65]. 
2.4.1 MRMR (Minimum-Redundancy-Maximal-Relevance) 
mRMR [66] is a feature selection method based on mutual information. It attempts not only to 
maximize the relevance among selected features and a class label, but also to minimize the 
redundancy between selected features. Since a set of best features does not result in the best 
feature set, eliminating redundant features is important to provide a good subset of features. Both 
relevance and redundancy are characterized in terms of mutual information as follows:  
maximal relevance: maxD,o, V., p = 1|q|∑ r,-; V.t\∈q  
minimal redundancy: maxR,o., v = 1|q|w∑ r"-; -&t\,t]∈q  
where I(x,y) is the mutual information of two variables x and y, S is the feature set, and c is the 
class label. To achieve the goal of optimizing above two conditions simultaneously, the simple 
mRMR criterion, max,p − v., is invoked. It starts from a feature with the highest maximal 
relevance, and a new feature is selected and added to the current feature set if it satisfies the 
mRMR critetion among the rest of features. Thus, it generates, in fact, the order of the features 
according to the mRMR criterion. 
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2.4.2 Sequential Floating Forward Selection (SFFS) 
SFFS sequentially adds new features followed by conditional deletion(s) of already selected 
features. Starting with the Ccandidate, it searches for a feature - ∉ Ccandidate that maximizes the 
classification performance among all feature sets Ccandidate ∪ +-/, and adds it to Ccandidate. Then, it 
finds a feature 	- ∈ Ccandidate that maximizes the performance among all feature sets Ccandidate – 
+-/. If the removal of x improves the highest performance obtained by Ccandidate, x is deleted from 
Ccandidate. As long as this removal improves upon the highest performance obtained so far, the 
removal step is repeated. SFFS repeats the addition and removal steps until the performance 
reaches at Pbest or the number of additions and deletions exceeds Nad, and the feature set with the 
highest performance thus far is chosen as the optimal feature set. The classification capability of 
a feature set, required for feature selection, is obtained by cross-validation on the dataset set. 
SFFS can be directly applied to the original feature set; however, conducting the first stage may 
help to reduce the search space and time and to build the optimal classifier by providing a good 
initial feature set for SFFS.  
2.5 Samples and Data Preparation 
H&E stained images were acquired on a standard optical microscope at 40x magnification, and 
the size of a pixel is 0.963um x 0.963um. IR spectroscopic imaging data from the TMAs were 
acquired at a spatial pixel size of 6.25µm x 6.25µm, a spectral resolution of 4 cm-1 at an 
undersampling ratio of 2 using a Perkin-Elmer Spotlight imaging system. The spectral profile of 
a pixel was truncated to a spectral range of 4,000–720 cm-1. Tissue samples were sectioned to ~7 
micron thick sections, with a section being placed on IR transparent BaF2 slides and a serial 
section on a standard glass slide. A set of formalin-fixed and paraffin-embedded tissue samples 
is incorporated into a tissue microarray (TMA). Each dataset has two TMAs. One is H&E 
stained image and the other is IR image. Unfortunately, we were not able to use all of these 
tissue samples in the TMAs for several reasons. Since these were experimental arrays, some 
TMA spots were missing in one or both arrays due to processing and plating on the salt plates 
used for IR analysis. Some tissue samples were spatially displaced and fused with neighboring 
tissue samples. 
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2.6 Figures 
 
Figure 2.1: IR imaging data and its use in histologic classification. (Upper row) IR imaging 
data (b) is acquired for an unstained tissue section (a). The data is then classified into cell types 
and a classified image (c) is obtained. The colors indicate cell types in a histologic model of 
prostate tissue. This method is robust and applied to hundreds of tissue samples using the tissue 
microarray (TMA) format. (Lower row) H&E (d) and IR classified (e) images of a part of the 
TMAs used. Black and white scale bars represent 500 . 
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Chapter 3  
Related Work 
 
 
3.1 Histopathological Image Analysis for Cancer Pathology 
A vast amount of efforts has been made to develop automated systems for cancer diagnosis as 
recognizing the significance of quantitative analysis of histopathological images. Microscopic 
image of stained tissue serve as a basis of most of the work and alterations and changes at the 
tissue- or cellular-level have been extensively investigated. The systems, in general, include pre-
processing, feature extraction, and prediction steps [67]. Pre-processing is the step to reduce the 
effect of noise, artifacts and staining variability. Feature extraction is to quantify the properties of 
tissue. To obtain morphological features, prior to feature extraction, segmentation is often 
performed to identify histologic objects of interests, for example, epithelium, stroma, nuclei, and 
gland. Prediction tasks can be distinguishing cancer tissue from benign tissue, identifying grade 
of tissue, and recognizing distinct tissue compositions. 
The automated systems include methods to identify distinct tissue compositions [68, 69] [70] 
as well as methods for automatic grading and cancer detection [71-79]. The majority of these 
methods have extracted texture and/or morphological features to characterize tissue samples. 
Histologic objects such as nuclei lumen, or gland have been mainly used to extract 
morphological features [70-72, 75-78, 80]. Fourier Transform [73], Wavelet Transform [74, 75, 
78], and Fractal Analysis [78, 79] have been the techniques commonly used to obtain texture 
features. In addition to these features, color [78] and graph-based [76] features have also been 
used. Tissue image blocks were classified into stroma, benign prostatic hyperplasia, prostatic 
intraepithelial neoplasia, and cancer [68]. Stroma, benign, and cancer areas were identified by 
[69]. Arif and Rajpoot [70] developed an automated nuclei detection method utilizing shapes of 
nuclei. Stotzka et al. [71] computed morphological features from epithelial nuclei and 
distinguished moderately and poorly differentiated tissue samples. A content based image 
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retrieval method was proposed to assist with pathology diagnosis based on the features derived 
from the position of cell nuclei [72]. Smith et al. [73] used texture features computed by 
adopting Fourier transform and Karhunen-Loe’ve transform and classified tissue into Gleason 
grade 1,2,3, and a combined group of 4 and 5. Computing features based on wavelet transform 
and co-occurrence matrices, tissue was classified into Gleason grades 2 through 5 [74]. A multi-
stage approach incorporating texture and morphological features was proposed by Farjam et al. 
[75]. Doyle et al. [76] extracted graph-based, morphological, and texture features  and classified 
each pair of tissue types: Gleason grade 3 vs. grade 4, grade 3 vs. benign epithelium, grade 3 vs. 
benign stroma, grade 4 vs. benign epithelium, grade 4 vs. benign stroma, and benign epithelium 
vs. benign stroma. Similarly, based on morhoplogical features from gland, Naik et al. [77] 
performed pairwise classification: Gleason grade 3 vs. grade 4, grade 3 vs. benign epithelium, 
and grade 4 vs. benign epithelium. Tabesh et al. [78] used color-based, texture, and 
morphological features and performed tumor vs. nontumore classification and high rade (grade 4 
and 5) vs. low grade (grade 2 and 3) classification. Conducting fractal analysis, tissues were 
classified into a combined group of grade 1 and 2, 3, 4, and 5 by Huang and Lee [79]. 
Morphological features describing gland properties were extracted and classified tissues into 
benign and malignant [80].  
Various types of features and datasets have been tested; likewise, numerous classifiers have 
been applied. Nonetheless, the choice of classifiers seems to have been less significant than the 
feature extraction step [78, 79]. Further, despite the above-mentioned lines of progress in 
automated diagnosis, an important concern is that the varying properties of images, due to 
acquisition settings [75, 80] and staining [81], may affect the classification results substantially. 
Although the variation in image quality and condition by different acquisition settings has been 
addressed in [75] [80], to the best of our knowledge, no previous method has been validated 
across data sets under different staining conditions.   
3.2 Predictive Tools for Disease Recurrence 
Precise prediction of clinical outcomes will be a great help for the decision-making process in 
cancer pathology. Many types of prediction tools are available and can be grouped into five 
categories: 1) Risk grouping 2) Look-up tables 3) Machine learning 4) Nomograms 5) Risk 
scoring. The principle of risk grouping is to group similar patients in their pathological 
19 
 
characteristics together and use them to assign a risk group (low-risk vs. high-risk) to a patient. A 
popular tool, developed by D’Amico et al. [82], uses clinical stage, biopsy Gleason sum, and 
PSA level and predicts biochemical recurrence of the patients, who underwent RP, external-
beam radiotherapy, or brachytherapy. Look-up tables are designed to predict pathologic stages at 
RP. Partin tables [83] [84] [85] utilize PSA level, clinical stage and biopsy Gleason sum to 
predict four different pathologic stages – organ-confined, established extracapsular extension 
only, seminal vesicle invasion, and lymph node involvement. Among various machine learning 
methods, two approaches have been popular, namely classification and regression trees (CART) 
and artificial neural network (ANN) [86]. CART learns a tree or a set of rules by splitting 
datasets based on a discriminative power of parameters. ANN learns a function or model by 
adjusting the weights associated neurons in the model. Nomogram [87] is a graphical tool 
incorporating several predictors, which include clinical stage, PSA levels, and Gleason grade, to 
predict the probability of a particular outcome, for instance, prediction of PCa on initial biopsy 
and repeat biopsy, pathologic stages, biochemical recurrence after RP, external beam 
radiotherapy, or brachytherapy, metastatic progression, and survival [22]. Risk scoring [30] [29] 
is to assign relative scores for the several variables such as Gleason score and clinical stage. 
Among them, CAPRA-S score [29] utilizes PSA level, Gleason score, surgical margin status, 
extracapsular extension, seminal vesicle invasion, lymph node invasion and predicts biochemical 
recurrence after RP.  
Though gained success to a certain extent, a great deal of efforts has been made to further 
improve the outcome prediction. Extra clinical information has been ineffective, but the 
additional information from novel bio- and imaging-markers such as gene expression [88] [89], 
immunohistochemical probes [90] [91] [92], magnetic resonance imaging [93] [94] [95], and 
tissue morphologology [90] [96] can be utilized to improve the cancer prognosis. Glinsky et al. 
[88] analyzed gene expression profiles of 12,625 transcripts in prostate tumors, identified 218 
differentially regulated genes in tumors, and found several gene clusters predicting the prostate 
recurrence after RP. Utilizing gene expression data, Stephenson et al. [89] built logistic 
regression models with and without clinical variables. The combined model performed better 
than the model only with gene expression data and the nomogram. Cordon-Cardo et al. [90] 
performed image and immunohistochemical analyses. Combined with clinical parameters, the 
recurrence prediction was made based on seven factors: 4 clinical parameters (lymph nodes, 
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surgical margins, biopsy Gleason score, and seminal vesicle invasion), 3 morpohlogical features 
(relative area of stromal and epithelial nuclear area and variation in the red channel of stroma 
mean) and 1 molecular feature (staining index of nuclear androgen receptor). Karnes et al. [91] 
assessed the association between the tumor protein levels of TOP2A and MIG-1 and ERG status 
by IHC analysis and found the prognostic ability was significantly improved for the patients with 
ERG (-) cancer. An automated method examining the expression of the cell cycle inhibitor p27 
in immunofluorescently stained tissue was developed by Anathanarayana et al. [92], and a 
significant relationship between p27 expression and prostate cancer recurrence was found. Cheng 
et al. [93] showed that erMRI staging combined with PSA level can be used to stratify patients 
with prostate cancer. This can help treatment planning. Combining clinical stage, PSA level, 
biopsy Gleason score, and pMRI findings with ANNs, Poulakis et al. [94] predicted 5-year PSA 
recurrence after RP. Shukla-Dave et al. [95] assessed findings from MRI/MR spectroscopic 
imaging and the expression levels of Ki-67, phosphor-Akt, and androgen receptor by IHC 
analysis. These two features were correlated each other and moderately strongly associated with 
clinical stage and biopsy Gleason score. An automate image analysis system was developed by 
Beck et al. [96]. Morphological features were extracted from epithelium and stroma and used to 
predict the recurrence of breast cancer. 
Combining the additional information with clinical parameters, in general, provides better 
prognosis. Notably, an important role of stroma in cancer progression has been reported [97] [90] 
[96]. Nevertheless, gene expression profiling and immunohistochemical staining are time-
consuming and/or expensive; tissue morphology extracted from the stained tissue is sensitive to 
the staining conditions and image acquisition settings as noted above; reading MR image is a 
manual process. Hence, these do not meet the needs for a high-throughput, objective, and 
operator-free method.  
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Chapter 4  
Analysis of Variance in Spectroscopic 
Imaging Data 
 
 
FT-IR imaging is a promising tool for analyzing biomedical samples and disease. It reveals the 
unique chemical characteristics of the samples and disease, which is encoded in the IR spectrum. 
The conventional approach lacks an appreciation of the limits of performance for the technology, 
however, which limits both researcher efforts in improving the approach and acceptance by 
practitioners. One factor limiting performance is the variance in data; analytic variability can 
arise from (a) noise in signal measurement, [47] [98] (b) differences within the tissue that leads 
to differences both within a given sample and between samples from the same patient, (c) 
differences between patients due to biologic diversity, (d) differences due to sample handling in 
different clinical settings or research groups and (e) causes not falling into any of the above 
categories. The variation may also be understood to be biological, technical or residual. 
Biological variation arises from different biological characteristics of samples such as patients, 
tissues, cells, subcellular components, etc. It is natural and expected variation, and often of 
interest in an experiment. Technical variation is attributable to both sample preparation and FT-
IR imaging techniques. Potential sources of technical variation include tissue acquisition [99] 
[100], fixation[101], and sectioning, placement of tissue section on the slide [100] and post-
preparation handling [102]. The very process of data acquisition also introduces variation, such 
as measurement noise [103]. Residual variation refers to the unexplained variation in the 
experiment; for example, environmental conditions – room temperature and humidity – that may 
not be part of the sample or acquisition characteristics. Although thoroughly identified, these 
potential sources of variation may never be complete. Accordingly, residual variation will be 
present and, on occasion, can have a substantial impact on the analysis. In such a case, we may 
either re-examine potential sources of variation and/or re-design the experiment. 
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Understanding the relative importance of each of these factors and explaining the variance 
observed in large scale tissue studies is critical for developing any real-world application. While 
an understanding of the contributions of variance by various sources can result in improved 
protocol designs, the lack of such understanding brings into question the performance of any 
developed protocol [104]. Hence, in this chapter, we develop a framework to understand analytic 
variability and its sources in IR spectroscopic imaging of tissue. This understanding may be 
extended to other analytical techniques and imaging modalities, in general, and may be used to 
improve the practice of IR spectroscopic imaging for biomedical analysis, in particular. The first 
challenge to understanding variability is to obtain a data set of sufficient diversity and size. 
Tissue microarrays (TMAs) [105], to this end, are an excellent tool and have been used 
previously in a number of studies [106] [107] [108] [51]. TMAs consist of many samples of 
tissue arranged in a grid pattern (Fig. 4.1), in which multiple samples are usually included from 
the same person and a population of different people is included. Multiple TMAs may further be 
employed to increase sample set diversity and size, both in the populations of patients as well as 
clinical settings and handling of samples. The second challenge is to quantify the effect of 
sources by determining their contribution to the total variance, which can be accomplished by 
applying analysis of variance (ANOVA) models to the acquired data set. ANOVA has been 
applied for analyzing several spectroscopic imaging data: chemical compounds [109] [110], 
collagen types [111], skin lesions [112], and plant species [113] [114] [115], but, to our 
knowledge, has not been applied to spectroscopic imaging of large data sets from tissues. 
In sum, we identify the sources of variation by first employing a high throughout sampling 
platform of tissue microarrays (TMAs) to record a sufficiently large and diverse set data. Next, 
we present appropriate analysis of variance (ANOVA) models (Table 4.1) for different 
experimental designs of IR imaging data from TMAs (FT-IR-TMAs), evaluate the statistical 
significance of the sources of variance, estimate variance contributions of the identified sources, 
and quantify the relative contributions of the sources to the total variation in the data. Finally, 
after examining the effect of the sources of variance, we also find the most discriminative 
spectral metrics and address the aspects of FT-IR imaging and TMA techniques that can be 
improved for better diagnostic protocols.  
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4.1 ANOVA Models 
4.1.1 Between-histologic Class ANOVA Model 
A TMA is comprised of many cores, in which one or more cores are obtained from a patient and 
cores are usually composed of pixels from multiple histologic classes such as epithelium, stroma, 
muscle, blood, and nerves, i.e., patients are “nested” within an array, cores are nested for each 
patient, and multiple histologic classes nested in a core. Accordingly, variability in IR 
spectroscopic imaging data from these cohorts is also distributed in a hierarchical fashion. 
Identifying six potential sources of variation (at the TMA level, between patients, within a core, 
within histologic class, measurement error, and an unexplained residual error) (Figure 4.1), we 
present the following ANOVA model (“between-histologic class model”) for this TMA design, 
#x =  + C + 	,. + N",.& + * + C* + 	*,. + N*",.& +6x + 
x (4.1) 
where y represents IR absorption of a pixel (y = 1,… , ) at a spectral metric of interest, µ is the 
overall mean, and α,	β, γ, and δ denote array (A = 1,… , ~), patient (m = 1,… , ), core ( =
1, … , ), and histologic class ( = 1,… , ) effect, respectively; to be specific, 	,. indicates 
the effect of jth patient within ith array. αδ,	βδ, and γδ are called interaction effects whereas α,	β, 
γ, and δ are designated as main effects. ω and ε represent measurement error and residual error 
effects, respectively. In contrast to the hierarchical structure of array, patient, and core effects, 
histology-associated effects span each of array, patient, and core effects. Hence, this design is 
called a partly nested ANOVA. Since both fixed (histologic class) and random (array, patient, 
and core) factors are present, it is also called a mixed effects ANOVA model. The corresponding 
ANOVA table is shown in Table A.1.2. 
The effect of the aforementioned factors and their individual variances can be estimated by 
computing an ANOVA table and applying the expected mean squared method which equates the 
observed and expected mean squares [58]. The total variance for the model (Eq. 4.1) can then be 
written as  
 = ~ + ,~. + ",~.& +  + ~ + ,~. + ",~.& + e +  
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where ~, ,~. , ",~.& , and  indicate variance components assigned to array, patient, core, 
and histologic class effects respectively, and e  and   are components of measurement error 
and residual error, respectively. ~ , ,~. , ",~.& , and   can be attributable to natural 
biological variation as well as pre-analytical technical variation arising from tissue handling and 
TMA preparation. e  belongs purely to technical variation and is separately estimated on the 
assumption that it follows an independent and identically distributed Gaussian distribution over 
the entire spectral region. This assumption is justified as the data undergo a FT, which 
redistributes noise in each recorded data point of the interferogram back into every spectral 
resolution element of the single beam spectrum [103]. To estimate the magnitude of this source 
of variance, we first compute the noise over a non-absorbing spectral region (1900-2100cm-1) 
and estimate the measurement error for each spectral metric.   incorporates the combined 
effects of biological variation that are not considered (for example, sampling variation), technical 
variation (for example, from processing, time of fixation) and other yet unexplained 
experimental variations. Hence, a good estimate and thorough inspection of residual error is 
critical to discovering effects that are not explained by the model and to correctly estimate the 
magnitude of variance that is yet to be explained. The variance arising from each factor could 
differ significantly across TMAs. In order to further examine the differences, we estimate the 
variance components for each TMA by restricting the (Eq. 4.1) ANOVA model to a single TMA. 
Hence, we fitted IR data of each TMA to the following model (“Within-array model”), 
#x =  + 	 + N,. + * + 	* + N*,. + 6x + 
x.  (4.2) 
Similarly, the total variance is  =  + ,. +  +  + ,. + e +  . This 
model is also a partly nested ANOVA. The ANOVA table for this model is available in Table 
A.1.3. 
4.1.2 No-histologic Class ANOVA Model 
Different histologic classes possess dissimilar chemical properties and cellular functions. 
Eliminating histologic class factor and other related factors from the (Eq. 4.1) model, we further 
examine the effect of histologic class on the data. The ANOVA model (“no-histologic class 
model”) can be expressed as  
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#x =  + C + 	,. + N",.& +6x + 
x.     (4.3) 
Since all factors are random, it is a nested random effects model. The total variance of data 
can be stated as  = ~ + ,~. + ",~.& + e + . The ANOVA table for this model is 
presented in Table A.1.4. Since heterogeneous histologic classes are merged into a core, 
biological variation may increase in the model. 
4.1.3 Within-histologic Class ANOVA Model  
Histologic classes are composed of a number of subcellular components (membrane, cytoplasm, 
nucleus, cytoskeleton, etc.). By further separating a histologic class into subcellular components, 
we can examine the effect of subcellular components for the histologic classes. The model is 
identical to the above (Eq. 4.1) ANOVA model except that the histologic class contribution is 
replaced with subcellular component contribution. Here, we restrict the model (“within-
histologic class model”) to a single array as follows: 
#2x =  + N + N2 + 62x + 
2x      (4.4) 
where  represents subcellular component ( = 1,… , 2) effect, which is fixed. This is a two 
factor crossed and mixed effects model, and the total variance is expressed as  =  +
 +  + e + . Table A.1.5 includes the ANOVA table for this model. As done in no-
histologic class model, eliminating subcellular component factor and interaction effect between 
subcellular component and core from the (Eq. 4.4) model, the following ANOVA model (“no-
subcellular component model”) is constructed: 
#x =  + N + 6x + 
x.       (4.5) 
This is a random effects model, and the total variance is expressed as  =  + e + .. 
The ANOVA table for this model is available in Table A.1.6. 
4.2 Measurement Error Estimation 
It is known that, in tissues, the spectral region between 1900cm-1 and 2100cm-1 has no molecular 
vibrational peaks, i.e., expect no IR absorption. Variations in this region could be either 
measurement noise or other processing errors such as baseline correction after eliminating 
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scattering effects. Since any variation is only attributable to measurement noise beyond the other 
processing errors, noise variance is estimated following all other processes. Considering the 
nature of data collection [103], we assume that the noise is independent and identically 
distributed over the spectral region and follows a Gaussian distribution with zero mean. This 
assumption is justified as we employ a fourier transform, which redistributes noise in each 
recorded data point of the interferogram back into every spectral resolution element of the single 
beam spectrum [103]. In order to estimate the noise variance, the individual noise variances are 
first computed for each wavenumber. Computing the mean of the individual variances, we obtain 
the estimate of measurement error variance. Afterwards, the noise variance for each spectral 
metric is estimated. A representative spectrum from a tissue sample is obtained and replicated 
10,000 times as adding Gaussian noise of the above noise variance to each wavenumber. This 
ensures that the signal is constant and the variation in the data is due to noise effects alone. 
Converting the noisy spectra into 93 spectral metrics, the noise variance of each spectral metric 
can be estimated (Figure 4.2). As shown in Figure 4.2, noise variance estimates differ across 
different spectral metrics. Due to spectral metric computation (ratio, sum of IR absorption), noise 
variance can be amplified, and also it could be affected by processing error such as baseline 
correction. For example, 75th spectral metric in Figure 4.2 is a ratio of two peaks 1160 cm-1 and 
1168 cm-1. Owing to their relatively small difference compared to the noise variance, the metric 
value may be largely reliant on the noise, not the signal; hence, higher variance than other 
metrics may be obtained. 
4.3 Datasets 
Four TMAs, containing prostate tissue samples, were obtained from different sources (Tissue 
microarray research program at the National Institutes of Health and Clinomics Inc.). The four 
TMAs contain respectively (i) 86 samples from 16 patients, (ii) 123 samples from 40 patients, 
(iii) 121 samples from 80 patients, and (iv) 240 samples from 180 patients. We note that the unit 
of observation in a spectral analysis is a pixel, but, in designing TMAs, the unit of interest is a 
single tissue sample (called “core”) or a patient. The number of pixels, especially of a single 
histological type such as epithelium, often varies substantially across cores and resulting data 
imbalance may greatly affect the results of the analysis. Therefore, we do not employ the entire 
collection of pixels (or cores) in TMAs, but address the issue of data imbalance by taking sub-
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samples of cores and sub-samples of pixels within each core in an attempt to balance the data for 
each group. The assignment of pixels to histologic classes was provided by either an automated 
histologic recognition method using FT-IR imaging, described in Chapter 3, or a pathologic 
review. 
 
4.4 Results 
Four TMAs of prostate tissue samples from different sources and five ANOVA models (Table 
4.1) are employed to examine various sources of variation in FT-IR-TMAs.  
4.4.1 Discriminative Metrics for Histologic Analysis 
Three TMAs (i, ii, iii) were used in this experiment. From each TMA, 26 sample cores from 13 
patients, containing a sufficiently large number of both epithelial and stromal pixels (>200), were 
selected, and 200 pixels were randomly chosen from each histologic class in a core. This data 
selection is necessary to eliminate bias that may arise from specific sets or patients with unequal 
representation. The histologic segmentation was conducted by a Bayesian classifier [51], built on 
18 spectral metrics  and achieved >0.9 AUC for the receiver operating characteristic (ROC) 
curve for most cell type classification. Although several histologic classes are present in these 
samples, we only consider epithelium and stroma as these are the two major functional cell types 
important in diagnosing prostate cancer, for simplicity afforded by the small model and to 
prevent data imbalance as some classes are not present in all samples. While epithelium may be 
expected to be rather uniform in chemical content, the stroma collectively consists of many cell 
types; hence, the within-class heterogeneity in stroma is likely to be much greater. Thus, the final 
reason for choosing this 2-class model is to examine both biochemically homogeneous and 
heterogeneous cellular populations. Using ANOVA table (Table A.1.2) for between-histologic 
class model, the portions of total variance due to the associated factors (Figure 4.3a) were 
computed. An example of ANOVA table computation for one metric is shown in Table 4.2. As 
described above, by equating MS and EMS for each factor, the variances of the identified factors 
were estimated. The ANOVA table was computed for the all metrics individually. As a result of 
that, we found that 21 out of 93 metrics (Table A.1.7) are dominated by variance due to 
histologic class differences, i.e., the portion of the variance due to histologic class was the largest 
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among all the associated factors, and either array contribution or residual error introduced the 
most variation into the other 72 metrics. The largest contribution to variability in data arising 
from differences in spectral properties of histologic classes indicates that epithelium and stroma 
differ spectroscopically, independent of all other factors. Thus, the 21 histologic class-dominant 
metrics are capable of histologic analysis, and for the purpose of histologic discrimination, these 
metrics could serve as good candidates. It must be noted that not all metrics that such an analysis 
provides will be useful for classification. In fact, comparing the 21 histologic class-dominant 
metrics and the 18 metrics, previously identified as being most useful for a (Bayesian) cell-type 
classification scheme[51], 6 of them were common (Table A.1.7). Among the 15 remaining 
histologic class-dominant metrics, there are 10 absorbance ratios, 4 area of a spectral region, and 
1 center of gravity of a spectral region metrics. In 10 absorbance ratio metrics, the numerator 
positions are either the same or close (<30cm-1) to the numerator position(s) of one or more 
metrics in the 18 metrics for cell-type classification. These are likely associated with the same 
functional group or chemical bonding; for example, the ratio of the absorbance at 1236cm-1 to 
the absorbance at 1545cm-1 and the ratio between absorbance at 1226cm-1 and absorbance at 
1545cm-1 are included in the 18 metrics. Both absorbance at 1226cm-1 and 1236cm-1 are specific 
to nucleic acids. Denominator positions are also different for some cases, but these are often the 
most representative positions, for instance, amide I (~1650cm-1) and II (~1545cm-1). Although 
the absolute magnitude of the absorbance differs, the relative magnitude among different groups 
(e.g., histologic classes) tends to be the same, and thus the denominator positions may have little 
effect on the metric values. The 4 area of a spectral region metrics are not present in the 18 
metrics, but the positions showing the highest spectral absorbance in the 4 areas are included in 
the 18 metrics. Lastly, the peak center of gravity metric, in fact, overlaps with one of the center 
of gravity of a spectral region metrics among the 18 metrics. Thus, most of the 21 histologic 
class-dominant metrics revealed by ANOVA as candidate metrics for histologic discrimination 
seem to be redundant with the 18 metrics for cell-type classification. It is assumed that a 
comprehensive variance analysis, of the type reported here, would have included all possible 
variation that may be encountered. If the addition of potentially useful metrics does not provide 
an improvement in classification accuracy, there may be an undiscovered pre-analytic variability 
in the validation datasets or redundancy in the metrics. The two confounding effects may be 
sorted out using the calibration data. That is, optimizing the classifier, the varying or redundant 
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metrics tend to be avoided. Here, variance components only provide an indication of the likely 
ability of a single metric, not of the combined effects of multiple metrics or their relative 
importance. Hence, variance analysis is powerful in that it can identify whether a difference can 
be made between classes but is limited in identifying the set of metrics that are important for a 
classifier. Similarly, random contributors to the total variance can be combined to achieve better 
classification than that obtained using univariate analysis either due to an averaging effect. From 
this point of view, performing multivariate analysis (e.g., multivariate analysis of variance) will 
help to have a comprehensive understanding of the combined effects of the metrics and their 
importance.  
Patient contributions have very little effect on the total variation of the data, indicating that 
inferences made or models built on this data would not be susceptible to the patient population. 
We emphasize, however, that this is not universally true and will change depending on the 
classification task. It is generally expected that there would be significant biochemical similarity 
in epithelial and stromal cells in men as these cells perform the same specific functions in all. 
Although its contribution to the total variance is small, there is significantly larger variance 
between cores than between patients suggesting that the selection of cores must be made 
carefully, especially with due attention to the architecture and biology of the tissue. The prostate 
is organized into zones [11], which are known to be compositionally and functionally distinct. 
Yet, no effort was made to control for that variable in these TMAs. Hence, if finer epithelial 
analysis is required, the example illustrates that paying attention to zonal morphology is likely 
more important than considering patient variations in constructing TMAs. Since the size of a 
core is relatively small compared to the entire tissue or organ, it is likely that some of the 
selected cores are not representative of the zonal region of tissue. This stochastic effect is 
expected to be smaller as there is no biologic rationale for differences within a zone. We also 
note that the small number of core samples could affect the variance estimates. Hence, many 
array designs, including the ones used for training in our original prostate work [51], used up to 8 
cores per patient. We note further that interaction effects, by and large, were negligible except 
the interaction effect between core and histologic class. This is also a likely effect of the 
aforementioned zonal architecture of the prostate as both stromal and epithelial differences exist 
between zones.  Interestingly, there were 19 metrics which were dominated by variance between 
arrays (Table A.1.7). This is likely a contribution of pre-analytical variability in array preparation 
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and is a topic of much discussion in the biomarker community [116]. Should this be the 
dominant mechanism, there are several computational approaches that have been proposed to 
address array-based differences [117]. The discovery of a large number of metrics in which array 
variance dominates, though, emphasizes that this topic remains one that deserves attention. 
Further biochemical assessment should also be carried out to demonstrate the effects of sample 
preparation [101] that are likely responsible for array-to-array differences. Finally, we assessed 
the statistical significance of histologic class effect by computing F-test statistics (Table 4.2) and 
corresponding p-values as described in Chapter 2. The lower p-values indicate statistically 
significant differences between histologic classes, thereby the metrics bearing lower p-values 
may be able to distinguish histologic classes. As shown in Figure 4.3a, the larger portions of 
explained variance, the lower p-values were observed in general.  However, by definition, it is a 
relative significance of histologic class effect to the interaction effect immediately below it, not a 
significance of the effect regarding all the associated factors. Accordingly, it provides limited 
information and could not depict the importance of the associated factors as a whole. 
4.4.2 Subcellular Components Specific Metrics 
To examine the effect of subcellular components in a TMA (iv), pixels identified as epithelial 
were further divided into two subcellular components: cytoplasm-rich and nucleus-rich pixels. 
The division of epithelial cells into nuclear-rich and cytoplasm-rich sub-units is important as 
tumors often lose the polarity (basal nucleus and cytoplasmic tip) as well as functional 
(cytoplasmic fraction of the cell) morphology [11]. The chemical constituents of epithelium are 
homogeneous, and the two sub-units, in fact, share many of the same chemical compounds [118]. 
The chemical similarity may affect the spectral analysis and the variance contributions of the 
associated factors. The two types of pixels were selected manually upon review of absorbance 
and corresponding hematoxylin and eosin (H&E)-stained tissue images. 40 cores from 40 
patients were chosen, and 100 pixels for each of the two components were extracted to build 
within-histologic class model. As shown in Figure 4.3a, subcellular component effect is the 
dominant source of variation for only 9 metrics (Table A.1.7), and residual error is the second 
dominant source for the 9 metrics and the most dominant factor for the rest of the metrics. 
Although it is the primary source of variation for the 9 metrics, the variance estimate of 
subcellular component effect does not overwhelm that of other effects. This is contrary to the 
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huge differences observed between histologic effect and other effects in between-histologic class 
model. Thus, with the selected cytoplasm-rich and nucleus-rich pixels, we do not observe a 
notable spectroscopical difference between them [118] as observed in histologic class analysis. 
This result is consistent with the previous work [57] where ~0.72 AUC was obtained in 
classifying pixels into cytoplasm-rich and nucleus-rich pixels whereas >0.9 AUC was achieved 
in histologic segmentation. The lower classification performance or subcellular component 
contribution to the total variation is due to the similarity in the underlying chemical components, 
errors in selecting the cytoplasmic and nucleus pixels, or limitation in FT-IR imaging [57]. These 
cause both biological and technical variations in the data. Biological variations could be reduced 
by minimizing cytoplasm and nucleus segmentation errors or obtaining high-definition FT-IR 
imaging [119]. One drawback of IR spectroscopy imaging is its fundamental spatial resolution 
limit due to optical properties [120] [121] and instrumentation constraints [122]. The limitation 
greatly affects the quality and selectivity of IR imaging [123]; for example, the pixels in between 
two different components such as epithelium and stroma are often contaminated or contributed 
by both components, thereby their spectra seem to be the average of the two components [46] 
[119], leading to increase in biological variation. Even, the smaller and chemically similar the 
two sub-units significantly suffer from the averaging effect. Being able to obtain high-resolution 
IR images, attaining reasonable signal-to-noise ratio (SNR), will substantially alleviate the 
averaging effect as well as biological variation. The finer IR image will, in turn, reduce the 
segmentation error. We could lessen technical variation by performing repeated measurements of 
FT-IR imaging on the same TMAs or incorporating numerical methods [124] to correct for the 
data. Repeating IR imaging helps to correct measurement noise in data, and spectral distortions 
due to various reasons such as optical effects [125] [126] [127] can be adjusted to recover the 
intrinsic IR spectra. 
In addition, we computed F-test statistic for subcellular component effect. Analogous to the 
results from between-histologic class model, the larger explained variance due to subcellular 
component effect, the lower p-values we observed; however, the p-values were often too small, 
close to 0, misleading about the significance of subcellular component effect. Accordingly, F-
test could not effectively provide discriminative metrics whereas variance components suggest 
weakly discriminating metrics. We also note that the metrics, owning high variation from 
histologic class effect in between-histologic class model, were not dominated by subcellular 
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component effect in general (Figure 4.3a). This indicates that the chemical properties to 
distinguish histologic classes differ from the properties to differentiate subcellular components. 
4.4.3 Biological Variation Within a Core and Epithelium 
Making no differentiation between histologic classes in a core, we fitted the FT-IR-TMAs data, 
used to build between-histologic class model, into no-histologic class model, and the portions of 
total variance explained by each factor were computed. As shown in Figure 4.3b, residual error is, 
in general, the dominant source of variation over the 93 metrics. The effects of other factors were 
relatively small, and either array effect or core effect was mostly the second dominant source of 
variation. 16 metrics were dominated by array effect, of which 11 metrics were also array effect-
dominant metrics in between-histologic class model. In comparison with between-histologic 
class model, combining histologic classes, residual error substantially increased in many metrics, 
especially for the 21 histologic-class dominant metrics. Similarly, constructing the no-
subcellular component model using the data fitted into within-histologic class model and 
estimating the portions of variance, residual error dominated over the other effects in the entire 
93 metrics (Figure 4.3b). Compared to the variance components from within-histologic class 
model, we again observed significant increase in residual error for numerous metrics including 
the 9 subcellular component dominant metrics. Both histologic class and subcellular component 
factors group pixels similar in chemistry into the same group, as a result, decreasing biological 
variation. This suggests that biological variation is the main source of variation in residual error 
within a core and epithelium, especially for those 21 histologic-class dominant metricsc and 9 
subcellular component dominant metrics in the data. However, note that the interpretation of 
histologic class effect and subcellular component effect should be limited to the population under 
the experiment since both effects are fixed as described in Chapter 2. 
4.4.4 Differences in the Effect of the Factors Across TMAs 
In order to investigate the differences in variance estimates across TMAs, each data from each 
TMA was fitted to the within-array model. The proportions of variance estimates were, in 
general, very similar across TMAs, and, comparing to between-histologic class model, similar 
trends were observed for the main effects; 16 out of the 21 histologic-class dominant metrics 
(between-histologic class model) showed high variability due to histologic class effect across all 
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three TMAs; the rest of the metrics were mostly dominated by residual error across TMAs. 
Examining the 19 array-dominant metrics from between-histologic class model (Figure 4.5a), we 
observed the differences in the variance components of not only histologic class effect but also 
other main and interaction effects across TMAs. In Figure 4.5, for the first four metrics, although 
residual error was the most dominant source of variation, the relative orders of other factors 
varied greatly across TMAs; the next four metrics showed unusually high variability in Figure 
4.b  and moderate dominance in Figure 4.5d from histologic class effect, but, in Figure 4.5c, the 
effect was not dominant or its contribution is close to residual error; examining the last 11 
metrics, the differences in the portions of variance due to both main and interaction effects were 
also observed. For histologic analysis, these 19 array-dominant metrics may be avoided. The four 
metrics, in particular, introducing high variation from histologic class effect (Figure 4.5b) could 
be specific to the population represented by the TMA (i), and thus may distract the histologic 
analysis and its translation into clinical practice. Computing p-values of histologic class effect, as 
observed in between-histologic class model, metrics with higher variance components possess 
lower p-values. However, many of the metrics show very small p-values. Note that the 
computation of F-test statistic is not identical to between-histologic class model. Here, the 
denominator is the mean square of the interaction effect between histologic class and patient. 
The statistical significance is sensitive to the sample size. The degrees of freedom (df) of the 
denominator in within-array model is larger than that of the denominator in between-histologic 
class model whereas df of the numerators are the same. Hence, p-values become much smaller 
although the magnitude of the differences in histologic classes remains the same or slightly 
changes. 
Differences between TMAs, often from different sources, can be alleviated by standardizing 
the operating procedures or the management of tissue, for example maintaining biobanks [104]. 
These may help to reduce both technical and biological variations associated with TMA 
preparation. However, standardization of the process and quality management cannot be 
achieved without thoroughly evaluating the relevant factors and operations over the course of 
TMA preparation. In this regard, the variance analysis could also be an excellent tool to assess 
the procedures and to stabilize the processing and management protocol.  
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4.5 Conclusion 
In this chapter, ANOVA has been adopted to model IR imaging data from a large population and 
to identify the main sources of variation. Variation in recorded data arises from every aspect of 
the sample gathering (different biological characteristics of samples), processing (sample 
fixation, sectioning, and placement), data acquisition (measurement error) and analysis steps 
(baseline correction, normalization, and modeling). Although underwent the same procedures, 
the contributions of different factors varied across different spectral metrics, and the main source 
of variation was not identical, i.e., each of the associated factors affects different spectral metrics 
differently. Hence, thorough identification of the factors and careful quality control on them are 
indispensable to ensure the validity and reliability of tissue classification or analysis using 
spectroscopic imaging. Moreover, the approach is not specialized for FT-IR imaging and TMAs 
settings, which provided here, but minor modifications in the ANOVA model will be necessary 
to reflect the changes in an experimental design, if any. The framework provided here should 
prove useful for other tissue types, problems and analytical techniques.  
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4.6 Figures and Tables 
 
Figure 4.1: Schematic of TMAs and potential sources of variation. (Lower row) a number of 
cores from different patients compose a TMA. (Top, left) A cell type classified image of a tissue 
sample where colors indicate cell types in prostate tissue. (Top, right) The corresponding IR 
spectra of cell types are shown. ,	, , , and  denote array, patient, core, histologic class, and 
subcellular component effect, respectively.   and   refer to measurement error and residual 
error, respectively. White scale bar denotes 500 . 
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Figure 4.2: Variance estimates of measurement error over 93 spectral metrics. Replicating a 
representative spectrum, the noise variance in each spectral metric is estimated. The noise 
variance associated with each wavenumber is 4.04e-4. The spectral metrics are ordered by the 
portion of total variance due to histologic class effect in between-histologic class model. 
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Figure 4.3: Portions of explained variance with and without histologic class factor. The 
portions of total variance explained by the associated factors are estimated for (Top, a) between-
histologic class model and (b) no-histologic class model and plotted over 93 spectral metrics. 
(Botton, a) p-values for histologic class effect are shown at the bottom. (a,b) The spectral metrics 
are ordered by the portion of total variance due to  histologic class effect. Interaction effects are 
not shown for (a). 
38 
 
 
 
Figure 4.4: Portions of explained variance with and without subcellular component factor. 
The portions of total variance explained by the associated factors are estimated for (Top, a) 
within-histologic class model (b) no-subcellular model and plotted over 93 spectral metrics. 
(Bottom, a) p-values for subcellular component effect are shown at the bottom, and the blue 
boxes indicate that the corresponding metrics are histologic class-dominant. (a,b) The spectral 
metrics are ordered by the portion of total variance due to subcellular component effect. 
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Figure 4.5: Portions of explained variance for array-dominant metrics across TMAs. 
Portions of variance are shown for (a) no-histologic class model and (b,c,d) between-histologic 
class model restricted to each of (i,ii,iii) TMAs, respectively. Spectral metrics are ordered by the 
portion of total variance due to (a) array effect. 
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Table 4.1: Summary of ANOVA models in the manuscript.  
Between-
histologic 
class 
Objective 
Examines the effect of histologic class across TMAs. Helps determine 
whether a given metric can differentiate between histologic classes, 
overcoming all other sources of variance. 
Model 
#x =  + C + 	,. + N",.& + * + C* + 	*,. + N*",.& +6x + 
x  
Variance  = ~ + ,~. + ",~.& +  + ~ + ,~. + ",~.& + e +  
Within-
array 
Objective 
Examines the effect of histologic class within a TMA. Determines the ability 
of a metric to distinguish histologic classes within a data set, e.g. in 
calibration data. 
Model #x =  + 	 + N,. + * + 	* + N*,. +6x + 
x 
Variance  =  + ,. +  +  + ,. + e +  
No-
histologic 
class 
Objective 
Examines residual error across TMAs. Helps determine the change in 
residual error in the absence of histologic class effect across TMAs in 
comparison with between-histologic class model.  
Model #x =  + C + 	,. + N",.& +6x + 
x 
Variance  = ~ + ,~. + ",~.& + e +  
Within-
histologic 
class 
Objective 
Examines the effect of subcellular component in a histologic class. 
Determines the discriminative ability of a metric to identify subcellular 
components in a histologic class. 
Model #2x =  + N + N2 + 62x + 
2x 
Variance  =  +  +  + e +  
No-
subcellular 
component 
Objective 
Examines residual error in a core. Helps determine the change in residual 
error in the absence of subcellular component effect within a histologic class 
in a core, comparing with within-hisotlogic class model. 
Model #x =  + N + 6x + 
x 
Variance  =  + e +  
Here, y represents IR absorption of a pixel, and  is the overall mean. α,	β, γ, δ, and φ denote 
array, patient, core, histologic class, and subcellular component effect, respectively. αδ, βδ, γδ, 
and γφ are interaction effects. ~ , , , and  indicate variance components assigned to 
array, patient, core, histologic class, and subcellular component effects respectively, and e  and  are components of measurement error and residual error, respectively. Details of the symbols 
are presented in Table A.1.1. 
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Table 4.2: An example of ANOVA table for between-histologic class model.  
df, MS and EMS denote degrees of freedom, mean squares, and expected mean squares, 
respectively. A(B) denotes that factor A is nested within factor B. * indicates the interaction 
effect between factors.  
 
 
  
Source    df   MS EMS 
Array   2   0.01678 e +  + 400",~.& + 800,~. + 10400~ 
Patient(Array)   36    0.02462 e +  + 400",~.& + 800,~.  
Core(Patient(Array))   39   0.01345 e +  + 400",~.&  
Histologic class   1   46.9907 
e +  + 200",~.& + 400 + 5200~
+ 15600 
Array*Histologic class   2   0.01180 e +  + 200",~.& + 400 + 5200~  
Patient(Array)*Histologic class   36   0.01604 e +  + 200",~.& + 400  
Core(Patient(Array))*Histologic 
class   39   0.01356 e +  + 200",~.&  
Residual error   31044   3.443e-4  
Measurement error     4.601e-6 e  
    
F-test statistics (Histologic 
class)   3980.5  
p-value (Histologic class)   0.000251  
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Chapter 5  
Automated Histologic Analysis  
 
 
The structural changes in prostate tissue are characteristics of cancer. Histologic assessment of 
the changes by pathologists forms a gold standard of the current prostate cancer pathology but 
retains the issues of low-throughput, high medical expenses, and variability in grading. Although 
computer-aided methods have been developed to address them, the varying properties of 
histopathologic images, due to acquisition settings [75, 80] and staining [81], limit the utility and 
capability of such methods. As described in Chapter 3, the issue of image variation by different 
acquisition settings has been addressed in [75] [80], to the best of our knowledge, no previous 
method has been validated across data sets under different staining conditions. Recently, an 
automated recognition of prostate cell types has been successfully conducted using FT-IR 
imaging. Since it is non-perturbing and label-free imaging, it does not suffer from the above 
mentioned problems of stained images, that is, an objective, alternate and complementary 
information can be provided. Utilizing the additional information will benefit the existing 
prostate pathology.  
In this chapter, we develop a new fully-automated cancer classification method from 
microscopic imaging and FT-IR imaging. The classification algorithm uses morphological 
features – geometric properties of epithelial cells/nuclei and lumens – that are quantified based 
on H&E stained images as well as FT-IR images of the tissue samples. Integrating FT-IR image 
and stained image, we attempt to minimize the effect of varying quality of tissue images on the 
classification. By restricting the features used to geometric measures, we sought to mimic the 
pattern recognition process employed by human experts, and achieve a robust classification 
procedure that can produce consistently high accuracy across independent data sets. We 
systematically evaluate the performance of the new method through cross-validation, and 
examine its robustness across data sets. We also summarize the specific morphological features 
that prove to be most informative in classification. While we expected the chemical imaging 
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approach to prove useful in histologic analysis of prostate tissue, its relationship to the existing 
clinical practice of using H&E stained tissue in PCa diagnosis was not clear a priori. Hence, we 
sought to examine whether a combination of the two techniques (i.e., optical microscopy 
following H&E staining, and FT-IR imaging) could provide high accuracy diagnoses that could 
otherwise not be achieved using H&E images alone.  
We begin with a description of the computational pipeline. As noted above, a key aspect of 
our approach is the use of FT-IR imaging data on a serial section that is H&E-stained to enhance 
the segmentation of nuclei and lumens. The first two components of the pipeline are geared to 
this functionality, while the next two components exploit the segmented features obtained from 
image data to classify the tissue sample (Figure 5.1). Finally, the classification performance on 
two independent datasets and the effectiveness of FT-IR imaging on the classification are 
presented. 
5.1 Image Registration 
Given two images, the image registration problem can be defined as finding the optimal spatial 
and intensity transformation [128] of one image to the other. Here, two images are H&E stained 
(Ireference) and “IR classified” images (Itarget) which were acquired from adjacent tissue samples. 
The IR classified image represents the FT-IR imaging data, processed as indicated in Chapter 2, 
to classify each pixel as a particular cell type. Although the two tissue samples were physically 
in the same intact tissue and are structurally similar, the two images have different properties 
(total image and pixel sizes, contrast mechanisms and data values). Hence, features to spatially 
register the images are not trivial. The H&E image provides detailed morphological information 
that could ordinarily be used for registration, but the IR image lacks such information. On the 
other hand, the IR image specifies the exact areas corresponding to each cell type, but the 
difficulty in precisely extracting such regions from the H&E image hinders us from using cell-
type information for registration. The only obvious features are macroscopic tissue sample shape 
and empty space (lumens) inside the tissue samples. To utilize these two features and to avoid 
problems due to differences in the two imaging techniques, both images are first converted into 
binary images. Due to the binarization, the intensity transformation is not necessary. As a spatial 
transformation, we use an affine transformation (f) [128] where a coordinate (x1, y1) is 
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transformed to the (x2, y2) coordinate after translations (tx, ty), rotation by θ, and scaling by factor 
s.  
-# = 
t[ +  
cos 
sin
− sin 
cos   
-1#1 
Since two adjacent tissue samples are structurally similar, it is assumed that two images do 
not suffer from large deformation, and the affine transformation is sufficient to model the 
geometrical change between two images. Difficulty in extracting features, ascribed to different 
properties and information provided by two images, leads us to use entire image for estimating 
the transformation parameters. We define absolute intensity difference between two images as 
error metric (or similarity measure). The absolute intensity difference between two images is, in 
fact, corresponding to the total number of pixels where two images have different labels owing to 
binarization. The better registration, the smaller number of those pixels it results in. Thus, the 
optimal registration can be obtained by minimizing the absolute intensity difference between two 
images. In other words, the image registration amounts to finding the optimal parameter values 
of the affine transformation 
,t∗ , t∗ , ∗, ∗. = argmin£,¤,¥, ¦r§¨ − ^"r©; t, [ , , &¦. 
To reduce the search space, we align the center of two images and scaled up Itarget by 
estimating the radius of both samples. Afterwards, we draw random samples of the parameter 
values, transform the coordinate of Itarget, and compute the absolute intensity difference to obtain 
the initial solution. Then, the downhill simplex method [129] is applied to attain the final 
solution. An example of this registration process is shown in Figure 5.2 and qualitative validation 
of the registration is provided in Appendix (Table B.1). 
5.2 Identification of Lumen and Epithelial Nucleus 
While a number of factors are known to be transformed in cancerous tissues, epithelial 
morphology is utilized as the clinical gold standard. Hence, we focus here on cellular and nuclear 
morphology of epithelial nuclei and lumens. These structures are different in normal and 
cancerous tissues, but are not widely used in automated analysis due to a few reasons. First, as 
described above, simple detection of epithelium from H&E images is difficult. Second, detection 
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of epithelial nuclei may be confounded by a stromal response that is not uniform for all grades 
and types of cancers. We focused first on addressing these two challenges that hinder 
automatically parsing morphologic features such as the size and number of epithelial nuclei and 
lumens, distance from nuclei to lumens, geometry of the nuclei and lumens, and others. In order 
to use these properties, the first step is to detect nuclei and lumens correctly and we sought to 
develop a robust strategy for the same. 
5.2.1 Lumen Detection  
In H&E stained images, lumens are recognized to be empty white spaces surrounded by 
epithelial cells. In normal tissues, lumens are larger in diameter and can have a variety of shapes. 
In cancerous tissues, lumens are progressively smaller with increasing grade and generally have 
less distorted elliptical or circular shapes. Our strategy to detect lumens was to find empty areas 
that are located next to the areas rich in epithelium. White spots inside the tissue sample can be 
found from the H&E image by using a proper threshold value (>200) for the intensity of Red, 
Green, and Blue channels, and the pixels corresponding to epithelial cells can be mapped on the 
H&E image from the IR classified image through image registration. At least 30% of the 
perimeter of white spots is required to be next to or within the areas where epithelial pixels are 
present. Although restricting the white areas adjacent to epithelial cells, in our observations, 
many artifactual lumens are still present. Additionally, the size and shape of lumens are 
examined to eliminate such artifacts. The size of a lumen should be >10μm. The ratio of major 
and minor axis ratio (¬2/2) is greater than 3 when it is small (<100μm). Lumens are 
gradually smaller and lesser distorted as cancer progresses; that is, ¬2/2 is getting closer 
to 1, and larger ¬2/2is indicative of artifact. ¬2/2is computed by using the major 
and minor axes of an ellipse fitted to each white area. We note that while lumens are ideally 
completely surrounded by epithelial cells (called complete lumens), some tissue samples have 
lumens (called incomplete lumens) that violate this criterion because only a part of lumen is 
present in the tissue sample. To identify these incomplete lumens, we model an entire tissue 
sample as a circle, and the white spots between the tissue sample and the circle are the candidate 
incomplete lumens. As did in complete lumen detection, the same threshold value is used to 
identify white areas. To identify artifacts, we use heuristic criteria based on the size, shape, 
presence of epithelial cells and background around the areas as follows:: the fraction of their 
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perimeter bordering epithelial cells must be >0.65 and that bordering background must be <0.4, 
their size must be greater than 100μm, and ¬2/2< 3. In addition, the distances from the 
center of the tissue to the white spots are examined to identify the artifacts in crescent form 
which resulted from the small gaps between the tissue sample and the circle fitted to the sample: 
the average distance of their perimeter to the center of the tissue must be less than 90% of the 
radius of the tissue core. 
5.2.2 Nucleus Detection – Single Epithelial Cells 
Epithelial nucleus detection by automated analysis is more difficult than lumen detection due to 
variability in staining and experimental conditions under which the entire set of H&E images 
were acquired. Differences between normal and cancerous tissues, and among different grades of 
cancerous tissues, also hamper facile detection. To handle such variations and make the contrast 
of the images consistent, we perform smoothing [130] and adaptive histogram equalization [131] 
prior to nuclei identification. Adaptive histogram equalization is an image enhancement 
technique which redistributes each pixel value proportional to the intensities of its surrounding 
pixels. Because applying adaptive histogram equalization to all the three channels could bring 
dramatic alterations and biases in color spaces, we opt to apply to only green channel possessing 
the highest deviation. Nuclei are relatively dark and can be modeled as small elliptical areas in 
the stained images. This geometrical model is often confounded as multiple nuclei can be so 
close as to appear like one large, arbitrary-shaped nucleus. Also, small folds or edge staining 
around lumens can make the darker shaded regions difficult to analyze. Here, we exploit the 
information provided by the IR classified image to limit ourselves to epithelial cells, and use a 
thresholding heuristic on a color space-transformed image to identify nuclei with high accuracy. 
Superimposing the IR classified image on the H&E image, pixels corresponding to epithelium 
can be identified on the H&E image. These epithelial pixels are dominated by one of two colors: 
blue or pink, which arise from the nuclear and cytoplasmic component respectively. For nuclei 
restricted to epithelial cells in this manner, a set of general observations were made: 1) Red, 
Green, and Blue channel intensities are lower in nuclear pixels and higher in cytoplasmic pixels. 
2) Green channel intensity is lower than other channels in both cytoplasmic and nuclear pixels. 3) 
In stromal cells, which are not considered here, Red channel intensity is usually higher than other 
channels. 4) A difference between Red and Blue channel intensities is small both in cytoplasmic 
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and nuclear pixels. These observations led us to convert the stained image to a new image where 
each pixel has an intensity value |R + G – B|. (R, G, and B represent the intensity of Red, Green, 
and Blue channels, respectively.) This transformation, followed by suitable thresholding, was 
able to successfully characterize the areas where nuclei are present. The threshold values are 
adaptively determined as AVG,P. − ± STD,P. for Red and Green channels (Th³ and Th©) 
due to the variations in the color intensity. P represents a set of pixels where Red channel 
intensity if lees than either of two other channels (avoid to include stomal pixels). Finally, filling 
holes and gaps within nuclei by a morphological closing operation [132], the segmentation of 
each nucleus is accomplished by using a watershed algorithm [132] followed by elimination of 
false detections. To alleviate possible over-segmentation of the nuclei [133], we expand each 
segmented nucleus area N© by including all neighboring pixels whose intensities falling within 
AVG"N©& ± STD"N©&. The size, shape, and average intensity are considered to identify and 
remove artifactual nuclei: ¬2/2<4, size of a nucleus >5μm and <2×median size of all 
nuclei, and the average intensity<Th©. Figure 5.3 details the nucleus detection procedure. 
5.3 Feature Extraction 
As mentioned above, the characteristics of nuclei and lumens change in cancerous tissues. In a 
normal tissue, epithelial cells are located mostly in thin layers around lumens. In cancerous tissue, 
these cells generally grow to fill lumens, resulting in a decrease in the size of lumens, with the 
shape of lumens becoming more elliptical or circular. The epithelial association with a lumen 
becomes inconsistent and epithelial foci may adjoin lumens or may also exist without an 
apparent lumen. Epithelial cells invading the extra-cellular matrix also result in a deviation from 
the well-formed lumen structure; this is well-recognized as a hallmark of cancer. Due to filling 
lumen space and invasion into the extra-cellular space, the number density of epithelial cells 
increases in tissue. The size of individual epithelial cells and their nuclei also tend to increase as 
malignancy of a tumor increases. Motivated by such recognized morphological differences 
between normal and cancerous tissues, we chose to use epithelial nuclei and lumens as the basis 
of the several quantitative features that our classification system works with. (See examples of 
such features in Figure 5.4) It is notable that these observations are qualitative in actual clinical 
practice and have not been previously quantified. 
48 
 
5.3.1 Epithelial Cell-related Features  
Epithelial cell information is available from IR data. However, individual epithelial cells in the 
tissue are not easily delineated. Therefore, in addition to features directly describing epithelial 
cells, we also quantify properties of epithelial nuclei, which are available from the segmentation 
described above. The quantities we measure in defining features are:  
1) Size of epithelial cells: Number of epithelium pixels in a tissue. 
2) Size of epithelial nuclei: Number of epithelial nuclei pixels in a tissue. 
3) Number of nuclei in the tissue sample. 
4) Distance from a nucleus to the closest lumen (Figure 5.4h). 
5) Distance from a nucleus to the epithelial cell boundary: Epithelial cell boundaries are 
estimated by drawing a Voronoi diagram of the segmented epithelial regions (obtained 
from IR image) with the segmented nuclei serving as the Voronoi sites. The cell 
corresponding to each nucleus, also called the Voronoi cell, comprises all points that are 
closer to that nucleus than to any other nuclei. The Voronoi cell of a nucleus is considered 
as the epithelial cell to which the nucleus belongs, and the distance to the epithelial cell 
boundary is the distance from the center of the nucleus to the boundary of its Voronoi cell. 
6) Number of “isolated” nuclei: The number of nuclei that have no neighboring nucleus 
within a distance 20μm from the center of each nucleus.  
7) Number of nuclei located “far” from lumens: The fraction of nuclei which is >30 μm away 
from lumens.  
8) Entropy of spatial distribution of nuclei (Figure 5.4g): To measure the entropy of nuclei 
spatial distribution, an entire tissue is divided into N x N equal-sized partitions and the 
number of nuclei in each partition is counted. The entropy is computed as follows: 
H,Nuclei. = −! !º,-. log º,-.

01

01  
p() denotes the probability mass function of the number of nuclei in a partition. xij denotes 
the number of nuclei in (i,j)th partition.  
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5.3.2 Lumen-related Features 
Features describing glands have been shown to be effective in PCa classification [77, 80] . Here, 
we try to characterize lumens and mostly focus on the differences in the shape of the lumens. 
The quantities we measure in defining these features are:  
1) Size of a lumen: Number of pixels corresponding to a lumen. 
2) Number of lumens. 
3) Lumen “roundness” [80]: Roundness is defined as »¼½¾\»¿¾½¿ ¬  where À  is the perimeter of 
the lumen, À is the size of the lumen (i.e., number of pixels in the lumen), and r is the 
radius of a circle of  size À. 
4) Lumen “distortion” (Figure 5.4a): Distortion is computed as q:Á,ÂÃÄ.ÅÆÇ,ÂÃÄ. where À¨È  is the 
distance from the center of a lumen to the boundary of the lumen and AVG(·) and STD(·) 
represent the average and standard deviation. 
5) Lumen “minimum bounding circle ratio” (Figure 5.4b): Ratio of the size of a minimum 
bounding circle of a lumen to the size of the lumen. 
6) Lumen “convex hull ratio” (Figure 5.4c): Ratio of the size of a convex hull of a lumen to 
the size of the lumen.  
7) Symmetric index of lumen boundary (Figure 5.4e): Sum of Vertical and Horizontal 
Symmetry, that are defined as 
∑É»Ê\Y»Ë\É
∑É»Ê\X»Ë\É
 and 
∑É»Ì\Y»Â\É
∑É»Ì\X»Â\É
, respectively, where À:\  and ÀÍ\ are 
vertical distances from a vertical axis to the boundary of the lumen. À»\  and À³\  are 
horizontal distances from a horizontal axis to the boundary of the lumen. The vertical axis 
runs along the longest diameter, and the horizontal axis runs perpendicularly to the 
horizontal axis passing the center of the lumen. 
8) Symmetric index of lumen area (Figure 5.4f): Sum of left-right area symmetry and top-
bottom area symmetry are computed as |»Â¿¾½¿Y»Ì¿¾½¿||»Â¿¾½¿X»Ì¿¾½¿|  and 
|»Ê¿¾½¿Y»Ë¿¾½¿|
|»Ê¿¾½¿X»Ë¿¾½¿| , respectively, 
where À» , À³ , À: , and ÀÍ  are the size of left, right, top, and bottom 
quadrants, respectively. These quadrants are obtained by dividing the lumen through 
imaginary vertical or horizontal axes.  
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9) Spatial association of lumens and cytoplasm-rich regions (Figure 5.4d): Spatial association 
is computed as Î¿Ï]Î¿Ï]XÎÏ\Ð  where Ñ is a set of cytoplasm-rich pixels distant to lumens and 
Ñ  is a set of cytoplasm-rich pixels adjacent to lumens. The process of obtaining 
cytoplasm-rich pixels is provided in [57]. To obtain adjacent cytoplasm-rich pixels, we 
first searched the pixels around the boundary of lumens, and if a cytoplasm-rich pixel is 
found, then neighboring cytoplasm-rich pixels are searched. These are repeated until no 
more cytoplasm-rich pixels are found.  
Features 3) – 8) are various ways to summarize lumen shapes, while feature 9) is motivated 
by the loss of functional polarization of epithelial cells in cancerous tissues. 
5.3.3 Global & Local Tissue Features 
We have described above the individual measures of epithelium and lumen related quantities that 
form the basis of the features used by our classification system. Normally, these features have to 
be summary measures over the entire tissue sample or desired classification area. Hence, we 
employ average (AVG) or standard deviation (STD), and in some cases the sum total (TOT) of 
these quantities for further analysis. These features are called “global” features since they are 
calculated from the entire tissue sample. However, in some cases global features may be 
misleading, especially where only a part of the tissue sample is indicative of cancer. Therefore, 
in addition to global features, we define “local” features by sliding a rectangular window of a 
fixed size (25μmx25μm) throughout a tissue sample. For each window, AVG and/or TOT of the 
epithelium and lumen related quantities are computed. STD or extremal values (MIN or MAX) 
of the AVG and/or TOT values over all windows become local feature values (Figure 5.5). In all, 
67 features (29 global and 38 local features) are defined capturing various aspects of tissue 
morphology.  
5.4 Datasets 
Two different tissue microarrays were obtained from two different sources (Tissue microarray 
research program at the National Institutes of Health and Clinomics Inc.). The first dataset 
(“Data1”) consisted of 240 tissue samples from 180 patients, and the second set (“Data2”) 
includes 160 tissue samples from 80 patients. Unfortunately, we were not able to use all of these 
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tissue samples for several reasons. Each dataset has two TMAs. One is H&E stained image and 
the other is IR image. Since these were experimental arrays, some TMA spots were missing in 
one or both arrays due to processing and plating on the salt plates used for IR analysis.  Since our 
method focuses on epithelial cells, tissue samples which do not have enough epithelial cells 
(<10%) in either of two images (H&E and IR) were not considered in this study. Moreover, some 
tissue samples in Data2 are spatially displaced and fused with neighboring tissue samples. 
Eliminating those tissue samples, 66 benign tissue samples and 115 cancer tissue samples are 
remained for Data1, and 14 benign and 36 cancer tissue samples remained for Data2. An 
example of H&E images for both datasets is shown in Figure 5.6. 
5.5 Results 
5.5.1 Classification System Achieves AUC Greater than 0.97 on Both Datasets 
We first performed K-fold cross validation on each dataset. The data set was divided into K 
roughly equal-sized partitions, one partition was left out as the “test data”, the classifier was 
trained on the union of the remaining K – 1 partitions (the “training data”) and evaluated on the 
test data. This was repeated K  times, with different choices of the left-out partition (We set K = 
10). In each repetition, cross-validation on the training data was used to select the feature set 
with the highest AUC as explained in §4. The correct and incorrect predictions in the test data, 
across all K repetitions, were summarized into a ROC plot and the AUC was computed, along 
with specificities when sensitivity equals 90, 95, or 99%. Since the cross-validation exercise 
makes random choices in partitioning the data set, we examined averages of these performance 
metrics over 10 repeats of the entire cross validation pipeline. The average AUC for Data1 and 
Data2 were 0.982 and 0.974 respectively (Table 5.1, “feature extraction” = “IR & HE”). At 90%, 
95%, and 99% sensitivities, the average specificity achieved on Data1 was 94.76%, 90.91%, and 
77.80% respectively, while that on Data2 was 92.53%, 84.19%, and 49.54% respectively. SVM 
using the kernel parameter γ=1 is used here. This result is consistent with the classification 
results using different values of the parameter γ (See Appendix B.3 for details). We note that 
other classification methods can be also used. Among various methods, a logistic model tree 
[134], which combines linear logistic regression with decision tree induction, was used, and 
achieved slightly lesser performance than SVM (results not shown here). 
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 One way to interpret the above values is to examine our automated pipeline as a pre-
screening mechanism to identify the samples to be examined by a human pathologist. At a “true 
positive rate” of 99% (which means that only 1% of the cancer samples will be missed by the 
screen), the “false positive rate” is 22.2% (i.e., 22.2% of the benign samples will make it through 
the screen) on average for Data1 (Table 5.1), thereby reducing the workload of the pathologist 
by 4.5-fold. While the error rate of manual pathology determinations is generally accepted to be 
in 1-5% range, inclusion of confounding cancer mimickers raises the rate to as high as 7.5% 
[135]. Also noteworthy is the observation that the same algorithm performs consistently well on 
both data sets, that were obtained from different staining conditions. This speaks to the 
robustness of the classification framework, an attribute that we investigated further in the next 
exercise. 
5.5.2 Robust Classification to Staining Conditions 
Here, we trained a classifier on Data1 and tested its performance on Data2 (Table 5.2, “Dataset” 
= “Test”) using SVM with γ=1. We observed an average AUC of 0.956, with average specificity 
of 88.57%, 81.92%, and 26.86% at sensitivity equaling 90%, 95%, and 99% respectively (Table 
5.2, “feature extraction” = “IR & HE” and “Dataset” = “Test”). These values are competitive 
with the cross-validation results on Data2 (Table 5.1), where the training and testing were both 
performed on (disjoint parts of) Data2. It should be noted that in Table 5.2 “Dataset” = “Train” 
means that the classifier was not only trained but also tested on Data1, and thus the difference 
between the “Train” and “Test” rows does not refer to a difference in performance on the two 
data sets. As a classifier is trained on Data2 and tested on Data1, we obtained the average AUC 
of 0.855 and average specificity of 50.18%, 40.41%, and 12.33% at sensitivity equalling 90%, 
95%, and 99% respectively (See Appendix B.3 for details). The results are worse than both the 
cross-validation results on Data1 and the validation results on Data2. This may be due to the fact 
that the number of samples in Data2 is relatively small and much unbalanced. In addition, 
varying the parameter value γ of SVM, the results, by and large, are the same (See Appendix B.3 
for details).  
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5.5.3 Use of IR Data Improves Classification Performance 
To assess the utility of the IR-based cell-type classification, we repeated the above exercises 
after extracting features without the guidance of the IR data; i.e., epithelial cells were predicted 
from the H&E images (See Appendix B.2 for details). All of the features defined in 5.3 were 
used, except for “Spatial association of lumens and apical regions”, since the distinction between 
cytoplasm-rich and nuclear-rich region in epithelial cells was unclear in H&E images. The 
results from this disadvantaged classifier are shown in Tables 5.1 and 5.2 (“feature extraction” = 
“HE only”). For both types of experiments, we obtained lower average AUCs and specificity 
values. For instance, the AUC of cross-validation in Data2 (Table 5.1) dropped from 0.974 to 
0.880. Similarly, the results of validation between datasets (Table 5.2) were substantially worse 
now compared to the IR-guided classification, with the AUC dropping from 0.956 to 0.918. We 
also observed that the average AUC dropped in the absence of IR data as using different values 
of parameter γ for SVM (See Appendix B.3 for details). This indicates that the use of IR data, i.e., 
the improved epithelial identification, helps to attain better classification performance. We also 
note that other methods, if any, which could achieve high accuracy identification of epithelial 
cells may have the same impact with the IR data on the classification.  
Previously, Tabesh et al. achieved an accuracy of 96.7% via cross validation in cancer/no-
cancer classification [78]. Color, morphometric, and texture features were extracted, and all 
images were acquired under similar conditions. We note that our classification result (Table 5.1), 
based solely on morphology, is comparable to their result; however the software developed by 
Tabesh et al. was not available for evaluation in our data sets. Color and texture features could 
provide additional information; however, their robustness to different data sets is questionable, 
and their interpretation is not as obvious as that of morphological features, which are used in 
clinical practice. Different data sets may have varied properties which may be attributable to 
staining variations, inconsistent image acquisition settings, and image preparation. The 
performance of the same method based on texture features has been seen to greatly change from 
one data set to another [75, 78, 80]. Variations in staining may affect color features. In contrast, 
morphological features were shown to be robust to varying image acquisition settings [80]. 
Nonetheless, the quality of morphological features is subject to segmentation of histologic 
objects. Thus, any method based on morphological features will benefit from the IR cell-type 
classification. 
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5.5.4 Examination of Discriminative Features 
We examined the importance of each feature by its rank in the first phase of feature selection, 
based on its “relevance” to the class label (see Chapter 2, mRMR). Since different features (e.g., 
average or standard deviation, global or local features) based on the same underlying quantity 
(e.g., “lumen roundness”) generally have similar relevance, we examined the average relevance 
of features in each of 17 feature categories (Figure 5.7), for each data set. The relevance of 
features is consistent across cross-validation, and their frequencies are also constant (See 
Appendix B.4 for details) The complete list of the individual features and their relevance and 
mRMR rank (for Data1) is available in Figure 5.8. For Data1, lumen-related feature categories 
are most relevant in general, while epithelium-related feature categories are most important for 
Data2. It is surprising that the top 3 feature categories in Data1 (Figure 5.7, blue bars) – size of 
lumen, lumen roundness, and lumen convex hull ratio – have very low relevance in Data2, 
although we note that this may be in large part due to variations in staining and malignancy of 
tumors between the two data sets and differences in the size of two data sets. The comparable 
classification results on Data2 (Table 5.1, 5.2), in spite of the maximal relevance differences, 
may indicate the broadness of our feature set and the accuracy of our feature selection method 
and facilitate the application of the same classifier on different data sets. Nevertheless, a larger 
scale study may be necessary to precisely examine the differences between datasets and features. 
It is, however, noteworthy that examining the features (or feature categories) with highest 
relevance alone may be slightly misleading, because this examination does not account for 
redundancy among features.  
To further examine the most informative and non-redundant features, we inspected the 
optimal feature sets selected after both stages of the feature selection component. For both Data1 
and Data2, the selection of the features is consistent across all folds of cross validation. (See 
Appendix B.4 for details) In Figure 5.9, we show an example of three most frequently selected 
features for Data1: number of lumens (LSTD), lumen roundness (GAVG), and size of nucleus 
(GTOT). We note that these include both lumen and epithelium related features. Lumen roundness 
(GAVG) is the only one ranked high by maximal relevance (Figure 5.8), yet all three features are 
consistently chosen by the classifier, since they provide different, complementary information on 
a tissue: greater circularity of lumens and increase in the number of lumens and the size of nuclei 
indicate malignancy of a tissue. 
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5.6 Conclusion 
In this chapter, we have presented a means to eliminate epithelium recognition deficiencies in 
classifying H&E images for presence or absence of cancer. The method is entirely transparent to 
a user and does not involve any adjustment or decision-making based on spectral data. We were 
able to achieve very effective fusion of the information from two different modalities, namely 
optical and IR microscopy, that provide very different types of data with different characteristics. 
Several features of the tissue were quantified and employed for classification. We found that 
robust classification could be achieved using a few measures, which are detailed to arise from 
epithelial/lumen organization and provide a reasonable explanation for the accuracy of the model. 
The choice of combining the IR and optical data is shown to be necessary for achieving the high 
accuracy values observed. We anticipate that the combined use of the two microscopies – 
structural and chemical – will lead to an accurate, robust and automated method for determining 
cancer within biopsy specimens. 
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5.7 Figures and Tables 
 
 
Figure 5.1: Staining allows visualization of tissue features. (a) an unstained image has little 
contrast while (b) the application of H&E stain highlights nucleic acid-rich regions as blue and 
protein-rich regions at pink. (c) structure of a prostate gland. It is notable that the stain is 
universal in that it is not diagnostic of cell type or disease. The stain serves only to provide 
contrast that is subsequently used by a human to recognize cell types and diagnose disease. Black 
and white scale bars represent 500 . 
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Figure 5.2: Image registration. H&E stained images and IR classified images are first 
converted into binary images. The IR classified image is overlaid with the H&E stained image by 
affine transformation, with the optimal matching being found by minimizing the absolute 
intensity difference between two images. After registration, original annotations (color and/or 
cell-type information) of each image are restored. Black and white scale bars denote 500 . 
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Figure 5.3: Nucleus detection. Smoothing and adaptive histogram equalization are performed to 
alleviate variability in H&E stained image and to obtain better contrast. “RG – B” conversion 
followed by thresholding characterizes the areas where nuclei exist. Morphological closing 
operation is performed to fill holes and gaps within nuclei, and a watershed algorithm segments 
each individual nuclei. The segmented nuclei are constrained by their shape, size, and average 
intensity and epithelial cell classification (green pixels) provided by the overlaid IR image.  
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Figure 5.4: Examples features. Each panel shows one example feature, along with the 
distributions of the feature’s values for cancer (red) and benign (blue) classes. 
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Figure 5.5: Global and local feature extraction. Global features are extracted from the entire 
tissue sample, and local features are extracted by sliding a window of a fixed size across the 
tissue sample and computing summary statistics, such as standard deviation, of window-specific 
scores. In this example, the global feature “number of nuclei” has value 755, while one example 
position of the sliding window is shown, with “number of nuclei” = 29. 
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Figure 5.6: H&E images of two datasets. An example of H&E images of (a) Data1 and (b) 
Data2. Colors in cytoplasmic and stromal areas are clearly different whereas color of nuclei is 
less varied. Black scale bars denote 500 . 
 
 
 
 
Figure 5.7: Importance of 17 feature categories. The average “maximal relevance” of features 
belonging to each feature category is shown, for both data sets, sorted in decreasing order for the 
first data set. 
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Figure 5.8: List of features and their maximal relevance and “mRMR rank”. In the second 
column, G and L represent global and local features, respectively. AVG, STD, TOT, and MAX 
denote the average, standard deviation, total amount, and extremal value of features. * In 
computing local features representing “size of lumen”, two options are available: one is to 
consider only the part of the lumen within the window, and the other is to consider the entire 
lumen into account. Asterisk indicates that the former option was chosen. 
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Figure 5.9: Optimal features for distinguishing cancer and benign tissue samples. The three 
features shown here are most frequently present in the optimal feature set chosen by the 
classifier. 
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Table 5.1: Classification results via cross-validation. 
Dataset 
Feature 
Extraction 
AUC Sensitivity 
(%) 
Specificity (%) 
Mf 
AVG STD AVG STD 
Data1 
IR & HE 0.982 0.0030 
90 94.76 1.64 
13 95 90.91 1.62 
99 77.80 5.52 
HE only 0.968 0.0052 
90 91.64 2.26 
11 95 83.90 1.91 
99 53.43 13.65 
Data2 
IR & HE 0.974 0.0145 
90 92.53 7.11 
7 95 84.19 10.84 
99 49.54 22.51 
HE only 0.880 0.0175 
90 61.34 10.31 
8 95 22.21 10.06 
99 11.21 6.01 
AVG and STD denote average and standard deviation across ten repeats of cross-valdiation. Mf 
is the median size of the feature set obtained by feature selection from training data. Column 
“Feature Extraction” indicates if features were obtained using H&E as well as IR data, or with 
H&E data alone. The parameter γ of a radial basis kernel for SVM is set to 1. 
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Table 5.2: Validation between datasets. 
Feature 
Extraction 
Dataset 
AUC Sensitivity 
(%) 
Specificity (%) 
Mf 
AVG STD AVG STD 
IR & HE 
Train 0.994 0.0006 
90 98.30 0.68 
13 
95 96.58 1.10 
99 91.55 2.55 
Test 0.956 0.0089 
90 88.57 5.96 
95 81.92 5.28 
99 26.86 15.50 
HE only 
Train 0.986 0.0021 
90 97.77 0.97 
10 
95 91.56 2.49 
99 79.29 4.47 
Test 0.918 0.0100 
90 65.51 8.37 
95 46.14 7.53 
99 13.29 6.94 
A classifier is trained on Data1 and tested on Data2. AVG and STD denote the average and 
standard deviation. Mf is the median size of the optimal feature set. Column “Feature Extraction” 
indicates if features were obtained using H&E as well as IR data, or with H&E data alone. 
Column “Dataset” indicates if the performance metrics are from training data (Data1) or from 
test data (Data2). The parameter γ of a radial basis kernel for SVM is set to 1. 
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Chapter 6  
Automated Tissue Referencing 
 
 
When a pathologist examines a tissue sample, he/she looks at a stained image of the tissue and 
mentally compares it against a “database” of previous knowledge or information in books. In 
essence, the pathologist is matching structural patterns with samples they have seen earlier and 
mentally recalling the diagnosis made such that they can make the same diagnosis in the specific 
test case. Although they are well-trained and thoroughly examines the case, the decision may be 
in doubt due to the variability in grading. To aid and improve the diagnostic process, there have 
been several research efforts to develop automated systems for the detection and grading of 
prostate cancer. Though the previous methods claim to be accurate, the information that 
pathologists will obtain by using such methods may be limited since these only provide the 
predicted grade or status of tissue in general. The prediction also relies on the conditions of the 
training and testing datasets such as acquisition settings [75] [80] and staining [81]. Moreover, 
the gold standard of the previous systems was mostly Gleason grade of tissue. Due to variability 
in grading and the heterogeneous nature of cancer, tissues belonging to the same Gleason grade 
may possess different cellular, nuclear, or glandular sub-patterns. For these reasons, the 
sustainability of Gleason grading is in question [136] [137] [138]. Accordingly, a system built on 
Gleason grade is likely to bear potential for malfunction in clinical practice. To this end, an 
alternative method is needed to provide pathologists with comprehensive information of the test 
case and to train and evaluate the automated system in an effective, rigorous, and robust way. 
In this chapter, we report our work on a new computer information and management and 
decision-support system that consists of a database of pre-examined prostate tissues and a 
retrieval process (Figure 6.1). The database retains tissue images, clinical information, and one 
or more measurements of the structure of tissue. The retrieval process utilizes the 
structural/morphological features of the tissue sample image and provides tissue samples similar 
to the sample under consideration from the database. We emphasize that the system does not 
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provide a diagnosis but simply provides the closest matching cases that help a pathologist to 
make a diagnosis. To our knowledge, no such system currently exists. Our premise is that tissue 
samples that have the same grade and similar characteristics and patterns with the sample of 
interest will afford useful information to pathologists. Moreover, we propose to determine tissue 
similarity based on various structural properties of tissue, not solely on Gleason grade. 
Combining different structural components of tissue ensures better characterization of tissue 
structure, and thus more accurate measurement of tissue similarity can be made. Further, we use 
infrared (IR) chemical imaging data in building the automated system. This will help to stabilize 
and improve the system as shown in Chapter 5.  
We first describe the three key components of our new system – tissue similarity measure, 
tissue morphology measure, and tissue retrieval function. Combining the three components, the 
performance of the tissue retrieval is examined through cross-validation and presented.  
6.1 Morphologic Criteria 
Gleason grading system provides the most definite diagnostic information today. The similarity 
between tissue samples can be determined by Gleason grade; two samples of the same grade can 
be designated as similar samples. Due to the variability issue and heterogeneity in cancer, 
however, the similarity may not be precisely determined. Alternately, we sought to measure 
tissue similarity by quantifying tissue morphology. We defined 9 criteria to describe the 
structural properties of tissue: 1) Gland crowding 2) Gland roundness 3) Stromal reaction 4) 
Gleason score 5) Nuclear grade 6) Clefts 7) Lumen/gland ratio 8) Gland continuity 9) Cell 
separation. The details of the criteria are listed in Table 6.1. For each of the criteria, a tissue 
sample is assigned a score ranging from 0 to 2 or 3 except Gleason score which ranges from 6 to 
10. Using the scores of the 9 morphologic criteria, tissue morphologic similarity (TMS) between 
tissue samples is measured. Although well-defined and measured, the importance or relevance of 
each criterion differs. For example, the significance of Gland crowding score 1 may differ from 
that of Gland roundness score 1, and the difference between two samples having Gland crowding 
score 1 and 2 may not be identical to the difference between two samples owning Stromal 
reaction score 1 and 2. In these cases, the absolute values of the scores and the difference of the 
scores are identical. Recognizing the intrinsic relationship between scores and criteria, we utilize 
the distribution of each criterion score over the samples in the database. Regardless of the 
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absolute value of a score, two samples away from each other in the distribution of the scores of a 
criterion are likely dissimilar in terms of the criterion, and vice versa. Tissue similarity between 
two samples with respect to a morphologic criterion, hence, is related to the number of samples 
between them as ordered by the score for the criterion. Accordingly, let TMS,I1, I. be the 
tissue morphologic similarity between two tissue samples I1  and I  and computed as 
TMS,I1, I. = ∑ TMS,I1, I.Ò01  where TMS,I1, I. is the morphologic tissue similarity for 
ith criteria.  TMSÓ,d1, d. is calculated as follows: 
TMS,I1, I. = 1 −
∑ ℎ,.Ïw\ Y10ÏÕ\ X1 +
12 Mℎ"Õ & + ℎ"w &P
Ö  
where s  is the ith morphologic criterion score of a tissue sample I, ℎ,. is the number of 
samples having ith morphologic criterion score s, and Z is a normalization factor.  
6.2 Morphological Feature Extraction 
In order to quantify the nuclear and cellular morphology of epithelial and stromal cells and 
lumens, we adopt the same approach with Chapter 5. We first segmented lumens and nuclei in 
tissue by considering their color intensities and geometric properties. Using the segmented nuclei 
and lumens, we define a number of quantities measuring the morphologic changes in tissue, and 
the quantities include the size, number, distance, spatial distribution, and shape of epithelial 
nuclei and lumens. In total, we defined 26 quantities, of which 17 quantities were used in 
Chapter 5. The additional 9 quantities are: 
1) Number of stroma cells: Number of stroma pixels in a tissue. 
2) Minimum lumen distance: Minimum distance between lumens. 
3) Minimum gland distance: Minimum distance between glands. To find glands in a tissue, 
we first find neighboring nuclei for each lumen. Neighboring nuclei to a lumen are the 
ones present within the epithelial cells next to the lumen. Then, we find a subset of the 
neighboring nuclei C È which satisfy the following condition: 
∀V ∈ C È: Distance,V, . ≤ ×ØÙ"Distance,C È, .& +  × oÚp"Distance,C È, .& 
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where l is a lumen, Distance,V, . denotes the distance from a nucleus c to a lumen l, and 
AVG(•) and STD(•) indicates the average and standard deviation of •. Initially, m is set to 
1.5. At each iteration, nuclei which do not satisfy the criteria are eliminated for further 
consideration and m is increased by 0.01. Fitting an ellipse to the subset of the neighboring 
nuclei gives an estimate of a gland for the lumen. 
4) Ratio of lumen to epithelial cells: Ratio of the number of lumen pixels to the number of 
epithelial pixels in a tissue. 
5) Ratio of epithelial cells to stroma cells: Ratio of the number of epithelial pixels to the 
number of stroma pixels. 
6) Ratio of cell separation: Ratio of the number of separated epithelial nuclei to the total 
number of epithelial nuclei. Epithelial cells are designated as separated cells if their size < 
500 pixels and >90% of their boundary is next to stroma cells. 
7) Ratio of sheets of cells: Ratio of the number of nuclei which are not associated with any 
gland and do not belong to the separated cells to the total number of nuclei. 
8) Degree of cell dispersion: Degree of dispersion of a cell type can be measured by 
variance-to-mean ratio (VMR) [139]. It is defined as VMR=ÛwÜ  where   is the average 
number of the pixels labeled with a cell type and  is the variance of the number of the 
pixels labeled with the cell type. VMR is separately computed for epithelial and stroma 
cells.  
9) Spatial autocorrelation of cells: To compute spatial autocorrelation of a cell type, we adopt 
two measures: Moran’s I and Greary’s C. Moran’s I [140] can be computed as follows: 
I = ∑ ∑ y
∑ ∑ y,# − #$.,# − #$. ∑ ,# − #$.  
where n is the number of the pixels assigned to the cell type, w is a random variable 
representing a weight associated with each pair of the pixels, y is a random variable for the 
number of adjacent pixels containing the same cell type, #$ is the average of the number of 
adjacent pixels. For simplicity, y =1 if i and j are adjacent and y =0 otherwise. 
Similarly, Greary’s C [141] can be calculated as follows: 
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G = Y1∑ ∑ x\]Þ]Þ\
∑ ∑ x\]"[\Y[]&wÞ]Þ\
∑ ,[\Y[$.wÞ\ . 
Prior to compute spatial autocorrelation of a cell type, for each pixel, the number of the 
adjacent pixels labeled with the same cell type is computed. These counts are used to measure 
spatial autocorrelation. Both Moran’s I and Greary’s C are computed for epithelial cells and 
stroma cells, respectively. Computing local and global features as did in Chapter 5, 308 
morphological features are extracted from a tissue sample. 
6.3 Evaluation of Retrieval 
Among the entire feature set (308 in this case), the most informative feature subset is selected 
through the two-stage feature selection method described in Chapter 2. Throughout the feature 
selection procedure, the retrieval capability of a feature set is measured by normalized 
discounted cumulative gain (NDCG) [142],  which is a popular measure to evaluate ranking 
algorithms. Given a database p, and TMS scores, the performance of the retrieval function f for a 
query q at rank position T is computed as follows: 
ßpGÙ,à, ^; p, Úáo. =
∑ 2:âq,1,ã. − 1log,1 + .:01 Ö  
where ¬ indicates the tth closet sample to the query q, retrieved by the retrieval functionf, from 
the database D , and  Ö denotes the normalization factor. 
6.4 Tissue Matching 
Given a query (tissue sample image), its morphological features are extracted and used to search 
for similar pre-examined samples from the database. To retrieve the most similar samples, we 
adopt Ranking-SVM [61], which sought to learn a function mapping onto a ranking. That is, 
Ranking-SVM provides a complete ranking of the entire samples in the database for the query. 
The feature vector difference between a query and the samples in the database is used for 
retrieval. The true ranking is provided by TMS scores between query and the samples in the 
database. We note that if a sample in the database is highly ranked to the query, then the query 
should be highly ranked for the sample. Considering not only the ranking of the samples to the 
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query but also the ranking of the query to the samples in the database, we define the ranking of a 
sample to the query as  
väAå,à, I; p. = väAå-oØá,à, I; p. + väAå-oØá,I, à; p\I⋃à., A = 1,… , 
where Ranking-SVM,à, I; p.  denotes the ranking of the sample I  in the database p  to the 
query à . Based on the ranking, the top-T samples are retrieved. Since it is the sum of two 
rankings, it is likely that several rankings are tied. In such cases, the final ranking is determined 
by the ranking of the sample to the query, i.e., Ranking-SVM,à, I; p..  
6.5 Balanced Training 
The retrieval system is geared to provide only top-T closest samples, i.e., the rankings of high 
TMS scoring samples are of great interest in the new system. We address this issue in part by 
applying NDCG to measure the retrieval performance; however, while training the retrieval 
process, this should also be taken into consideration. Since Ranking-SVM tries to learn an 
overall ranking of the training dataset, biased or unbalanced training dataset may cause Ranking-
SVM to be biased and its retrieval capability may be limited. To prevent this, we sought to take 
roughly balanced sub-samples of the training dataset and trained Ranking-SVM on the sub-
samples. To obtain the roughly balanced training dataset, we first divide the total TMS score 
range into P equal-sized partitions. Then, ß number of pairs of samples from each partition was 
randomly selected. We set ß to the smallest number of pairs of samples in a partition. 
6.6 Results 
To assess the new system, we have collected 114 prostate cancer tissue samples. Clinical 
information (Gleason grade, age, surgery type, etc.) of the samples were prepared by pathologic 
review, and 308 morphological features were also extracted. The database we built here, 
therefore, contains 114 tissue images (of two different modalities) and their clinical information 
and 308 morphological features.  
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6.6.1 Tissue Morphologic Similarity Measure 
For 114 prostate cancer samples, we asked a pathologist to score them according to the 9 
morphologic criteria. The pathologist was kept completely blind to the previous diagnosis and 
clinical information of the samples. Provided with the scores for the 9 morphologic criteria, 
tissue morphologic similarity (TMS) was measured for all possible pairs of 114 tissue samples 
(Figure 6.2a). We note that TMS score is not evenly distributed, and mid-range score (5~6) is 
mostly dominant. Notably, only small number of pairs of samples gains a high TMS score, e.g., 
~2% of pairs of samples scores ≥8 (Figure 6.2b). Hence, the retrieval process, Ranking-SVM, 
may be biased in favor of the pairs of the samples possessing mid-range TMS scores as trained 
on this dataset.  
6.6.2 Performance of Tissue Retrieval System 
To evaluate the tissue retrieval system, we performed K-fold cross-validation (setting K=10). The 
entire dataset was divided into K roughly equal-sized partitions, one partition was left out as “test 
data” (or queries), the union of the remaining K – 1 partitions (the “training data”) was used to 
build the database where T similar samples are retrieved for each query (We set T=5). This was 
repeated K times with different choices of the left-out partition. In each repetition, the 2-stage 
feature selection was carried out on the training data via L-fold cross-validation (We set L=5). 
The average NDCG at rank position T of the tissue retrievals for the queries, across all K 
repetitions, was computed to measure the performance of the retrieval. To handle the imbalance 
of TMS scores in the dataset, a roughly balanced training dataset was formed by dividing the 
entire score range into P partitions (We set P=10) and randomly taking equal number of samples 
from each partition.  
Although we have computed TMS scores and used them to train and test the retrieval process, 
it is unclear what similarity score is good enough to provide useful information with pathologists 
as examining unknown samples. Requiring too high score is unrealistic because there are not 
enough samples available; as mentioned above, only ~2% of the training samples have similarity 
score ≥ 8 for a query (Figure 6.2b). Providing lower scoring samples is not beneficial to 
pathologists. In order to examine the retrieval performance in a broad sense, we changed a 
threshold similarity score ℎ from 0 to 8, and designated a sample as a good match to a query if 
their similarity score is ≥ ℎ. Then, we counted how many of the queries were provided with ßÇ  
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or more good matches (ßÇ=1,…,T). In Figure 6.3a, it is noticeable that ~80% and ~60% of the 
queries retrieving ≥4 and ≥3 good matching cases as setting ℎ  to 5 and 6, respectively. 
Compared to the random chance of retrieving ≥4 and ≥3 good matches, both were increased by 
more than two-fold, and the retrievals were statistically significant (p-value <1.0e-10) (Table 
6.2). As shown in Figure 6.3b, it is obvious that TMS scores of pairs of the query and its T 
matching samples are higher than those of pairs of the query and all the samples in the database, 
especially TMS scores are 6 or greater.  
6.6.3 TMS Score Reveals the Complicated Relationship Between Tissues 
We examined the effectiveness of TMS scores in retrieving similar tissue samples. In Figure 6.4, 
examples of queries and their matching cases are presented. A pair of samples belonging to the 
same grade tends to have a high TMS score, for example, in the first row of Figure 6.4, two 
retrieved samples with Gleason sum score 6 have >7 TMS score for the query whose Gleason 
sum score is 6. Other three samples have different Gleason sum score but still possessing high 
TMS scores. However, high TMS scoring sample pairs are not necessarily to be the same grade. 
In the last row of Figure 6.4, none of the retrieved samples are diagnosed with the same Gleason 
sum score with the query, but their TMS scores are fairly high. Four of them have >6. 6 TMS 
score, of which each has identical scores with the query for at least 4 morphologic criteria except 
Gleason score. These types of relationships between samples can never be retrieved or assessed 
if an automated system is built solely on Gleason grading system. Thus, TMS scoring system 
may help to analyze the complicated and complex tissue morphology and to broaden our 
understanding. 
6.6.4 Towards Clinical Application 
It should be noted that the limited size of our database may substantially affect the performance 
of the retrieval system. In tissue retrieval, it is assumed that the database contains enough 
number of similar samples to any kind of query. The distribution of TMS score for one query 
differs from another. Some may have many high scoring sample pairs, but some may have few of 
them. In the latter cases, the retrieval system may return the most similar samples, i.e., the 
retrieval is valid and useful, but it is a seemingly bad retrieval due to relatively lower TMS score. 
In fact, as we trained Ranking-SVM on the entire training dataset, i.e., without balanced training, 
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less number of samples owning higher TMS scores with the query were retrieved (Figure 6.5), 
for example, TMS score ≥6. Accordingly, taking roughly balanced subset of the training dataset 
is a valid decision and helps to provide a more effective and robust retrieval process. Thus, for 
better and comprehensive evaluation, a large-scale validation study is highly desirable. 
Here, we only retrieved the 5 closest samples to a query. The more samples we retrieve, the 
higher chances we can provide good matching cases with pathologists. However, retrieving 
many samples (e.g., >10) will be another burden to pathologists due to additional time and effort 
to decide what samples are relevant and useful. Hence, providing a few, most similar samples 
would be more helpful and effective. It necessitates little time and work from pathologists to 
judge on the retrieved samples, but deliver fairly good matches. We note that if a pathologist 
would like to retrieve more or less samples, then the retrieval system should be re-trained by 
adjusting the number of retrievals. Moreover, as one or more morphological properties are of 
interest to a pathologist, the similarity score can be re-computed and used to train the retrieval 
system. Therefore, the system is potentially, highly adaptable to users’ demand and purpose.  
6.7 Conclusion 
In this chapter, we developed a time- and cost-effective information management and decision-
support system for cancer pathology. Both pathologists and patients can take advantage of the 
system in the clinical practice of cancer pathology. Here, the system has been developed and 
tested for prostate cancer, but the same system can be developed for other types of cancer. The 
system consists of two components: a database allows pathologists to easily manage and 
maintain the previous cases and outcomes, and immediate access to them is available due to 
efficient retrieval algorithm. Accordingly, the performance of tissue retrieval is reliant on both 
database and matching algorithm. Hence, further study on the matching algorithm, performance 
measure, and data handling, e.g., data normalization, would be necessary, and a large-scale 
validation study should be conducted to optimize and stabilize the system for various queries, 
tasks and users’ demands. Nevertheless, we anticipate that this approach will open a new 
direction for the development of automated methods for cancer pathology. 
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6.8 Figures and Tables 
 
Figure 6.1: Overview of referencing system. As a query is given, the closest matches and their 
clinical information are retrieved from the database (red arrows). Provided with the matching 
cases, pathologists make a diagnosis (blue arrows), and updating may or may not be conducted 
(yellow arrow). Q, D, Ranking, f, and S denote a query, database, retrieval process, single 
feature, and subset of features, respectively. Black scale bars denote 500 . 
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Figure 6.2: Tissue morphologic similarity measure. (a) Tissue morphologic similarity scores 
are computed and drawn for all possible pairs of tissue samples. (b) The frequency and 
cumulative density of similarity scores are plotted. Mid-range scores (5~6) are mostly dominant, 
and high scoring (≥8) samples are very rare. 
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Figure 6.3: Queries retrieving good matching cases. (a) The number of queries retrieving at 
least èé number of good matches, out of T retrieved samples, is computed (ßÇ = 1, . . . , Ú), and 
compared to the random chance (R0~R9) of retrieving that number of good matching cases. (b) 
The frequency and cumulative density of similarity scores are plotted for the entire training 
samples and T matching samples, respectively. A good matching case is defined as a pair of 
samples whose similarity score is ≥ℎê , ℎ=0,…,8. Random chance of retrieving ≥ßÇ  good 
matching cases is computed as j¬,ë ≥ ßÇ. = ∑ M
èêêì PMèêYèêêíYì P
MíPìgèé
 where ßq and ßqq denote the 
number of samples in the database and the number of samples whose TMS with the query ≥ ℎ, 
respectively. 
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Figure 6.4: Examples of queries and their matching cases. TMS denotes tissue morphologic 
similarity score for a pair of samples. GS indicates a sum of predominant and secondary Gleason 
scores. 
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Figure 6.5: Queries retrieving good matching cases without balanced training. (a) The 
number of queries retrieving at least ßÇ  number of good matches, out of T retrieved samples, is 
computed (ßÇ=1,…,T), and compared to the random chance (R0~R9) of retrieving that number 
of good matching cases. (b) The frequency and cumulative density of similarity scores are 
plotted as retrieval process is trained on balanced training dataset and unbalanced training 
dataset, respectively. A good matching case is defined as a pair of samples whose similarity 
score is ≥ℎ, ℎ=0,…,8. Random chance of retrieving ≥ßÇ good matching cases is computed as 
j¬,ë ≥ ßÇ. = ∑ M
èêêì PMèêYèêêíYì P
MíPìgèé
 where ßq  and ßqq  denote the number of samples in the 
database and the number of samples whose TMS with the query ≥ℎ, respectively. 
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Table 6.1: Morphologic criteria.  
Criteria Description 
Score 
0 1 2 3 
Gland 
crowding 
Gland tightness and 
cohesiveness 
N/A Sparse Moderate Very tight 
Gland 
roundness 
Roundness of external 
perimeter of gland 
N/A 
Very 
round 
Moderate 
Serrated 
contours or 
spindle shaped 
contours 
Stromal 
reaction 
Swollen, plump cells in 
stroma and splayed 
collagen fibers 
N/A 
No 
reaction 
Little  
Gleason 
Score 
Predominant and 
secondary Gleason score 
- - - - 
Nuclear 
grade 
Prominent nucleoli, 
variation in nuclear 
diameter and amount of 
chromatin 
N/A Normal 
Some 
prominent 
nucleoli, 
moderate 
variation 
Many 
prominent 
nucleoli, large 
variation 
Clefts 
Cleft formation or 
retraction artifact around 
cancer glands 
N/A <30% ≥30% - 
Lumen/glan
d ratio 
Ratio between lumen 
area and total gland area 
N/A 
Wide 
lumen 
Moderate lumen Tiny lumen 
Gland 
continuity 
Continuous sheets of 
cells 
N/A <30% ≥30% - 
Cell 
separation 
Individual cells separated 
by stroma 
N/A <10% ≥10% - 
Description of 9 morphologic criteria to determine tissue similarity. 
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Table 6.2: Statistical significance of tissue retrieval.  
 ℎ 
5 6 7 
ßÇ  
3 
101 
<0.001 
66 
<1.e-10 
12 
<0.0001 
4 
91 
<1.e-16 
33 
<1.e-11 
3 
<0.01 
5 
43 
<1.e-12 
6 
<0.001 
0 
1 
The number of queries (ßî) retrieving at least ßÇ  number of good matching cases as a good 
match is defined as TMS ≥ ℎ and its statistical significance. Assuming the number of good 
matches follows a binomial distribution, p-value is computed as 
j¬"ë ≥ ßî& = ∑ M- Ptgïð ºt,1 − º.2Yt where p is a random chance of retrieving ≥ ßÇ  good 
matches (TMS ≥ ℎ). (top) the number of queries and (bottom) its statistical significance. 
 
  
82 
 
Chapter 7  
Prostate Outcome Prediction 
 
 
Prediction of disease recurrence is an important practice to patient care. Currently, the outcome 
prediction is largely relying on the computational tools, but the constraints and weaknesses of the 
tools are evident as discussed in Chapter 1. Moreover, the existence of subtypes of cancer has 
been reported [143] [144]. That is, the characteristics of cancer could vary among the patients 
with the same kind of cancer. The predictive tools should consider not only the general 
properties of cancer but also the uniqueness of specific patients or a type of cancer. The 
variability or uniqueness of cancer, to our knowledge, has not been properly incorporated into 
the existing computational tools yet. Furthermore, many of the computational tools are largely 
relying on the clinical information such as PSA level, Gleason sum, and pathologic stages. The 
predictions for the patients with the same or similar status in that regard will be, by and large, 
identical, but their outcomes could greatly vary. In order to overcome the issues and improve the 
prediction, a variety of approaches has been adopted; however, heterogeneity and complexity of 
disease are the obstacles to developing new tools. Additional clinical information was incapable 
of refining the prediction. Novel bio- and imaging-markers, as noted in Chapter 3, are promising 
alternatives.  
In this chapter, we sought to improve the prediction of clinical outcomes (at 5 year after RP) 
from two different imaging modalities – microscopic imaging of a stained tissue and FT-IR 
imaging of an unstained tissue. Through the microscopic imaging of a stained tissue, the spatial 
property, i.e., morphology of the tissue is examined, and chemical information, related to the 
molecular characteristics, is obtained from FT-IR imaging. Since distinctive cell types, e.g., 
epithelium and stroma, greatly differ in morphology, chemistry, and function, their 
characteristics are assessed separately. Adopting a frequent pattern mining method and a 
ranking-based approach, we attempt to learn patterns which distinguish recurrence from non-
recurrence subjects and are independent of clinical status of patients. The performance of our 
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new method is compared to the two prominent tools, namely Kattan nomogram and CAPRA-S 
score. We also present the most informative morphological or chemical features in outcome 
prediction. Further, we examine if the combination of the new features and the existing tools 
could yield improved PCa outcome prediction.  
The rest of the chapter is organized as follows. First, we describe the extraction of 
morphological features from the microscopic imaging of a stained tissue via segmentation of 
histologic objects and quantification of their properties. Second, the computation of chemical 
features from FT-IR imaging is explained including discretization of FT-IR image and frequent 
pattern mining and pruning. Third, the classification performance of the method is presented and 
compared to the existing tools. Fourth, the effect of the combination of our method and the two 
existing tools is explored. Last, the selected features for classification are presented and are 
related to biological functions or activities. 
7.1 Morphological Features 
In prostate tissue, epithelial cells and stroma cells possess distinct properties and functions. The 
characteristics of epithelial cells change in cancerous tissues and form a gold standard of current 
prostate cancer pathology. The important role of stroma cells in cancer progression has been 
recently reported [97] [90] [96]. While we examine epithelial morphology through epithelial 
nuclei and lumens, stromal nuclei are utilized to examine stromal morphology. Not only their 
individual properties but also their interactions may be useful for delineating cancer 
aggressiveness. To assess the interactions, we also consider the relationship between different 
histologic objects; for example, minimum distance between stromal nucleus and epithelial 
nucleus. Examining these individual and relational properties necessitates accurate detection of 
epithelial and stromal cells. 
Prior to segmentation, we convert the color space of a tissue image into Lab color space 
[145], which approximates human perception of color and provide three channels – L for 
lightness, a and b for color-opponent channels. In order to reduce the effect of noise and to 
incorporate the neighboring pixel information, Gaussian smoothing is applied with varying sizes 
(σ = 1.6 × 2 ,  = 0,1,2,3). In total, 12 Lab features are generated for each pixel in tissue image. 
Adopting Logistic regression model, we classify each pixel into epithelium, stroma, nucleus and 
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others. We note that the epithelium and stroma segmentation can be provided from FT-IR 
imaging through image registration as in Chapter 5. 
7.1.1 Lumen Detection 
Lumens are recognized as empty white spaces surrounded by epithelial cells. Applying a proper 
threshold value (>200) for the intensity of Red, Green, and Blue channels, white areas can be 
detected, and >70% of their perimeters are required to be adjacent to epithelial cells. Also, the 
size of a lumen should be >60μm. Since lumens are lesser distorted and gradually smaller as 
cancer progresses, for smaller lumens (<170μm), an additional rule (¬2/2 < 3.0) is 
invoked. In addition to lumens, retraction clefting, due to the detachment of stroma cells from 
epithelial cells, are often found as empty white spaces in tissue and are known to be related to 
cancer progression [146]. To identify them, the same threshold value is applied, but restricting 
them to be encompassed by both epithelial cells and stroma cells (30%<fraction of epithelial 
cells<70% and 30%<fraction of sroma cells<70%). Contrary to lumens, smaller clefts (<170μm) 
should not be round or elliptical (¬2/2 > 3.0). 
7.1.2 Nucleus Detection 
The detection of nuclei is performed in 3-stage. In the first stage, we obtain the initial 
segmentation of nuclei by Logistic regression model. The same 12 Lab features are generated 
and Logistic regression model identified nuclei areas from other cell types (epithelium and 
stroma). For training, 69,881 nucleus pixels are provided from tissue images. Examining the 
neighboring cells of each nucleus, if ≥50% of them is an epithelial cell, then it is designated as 
epithelial nucleus. Otherwise, it is labeled with stromal nucleus. Epithelial nuclei, in particular, 
tend to clump together and to look like one large blob. In these cases, the detection is 
confounded and often makes many false positives, i.e., identifying background areas (also 
epithelium or stroma) as nuclei. In the second stage, for each identified candidate areas of nuclei, 
we group similar pixels together by applying multi-threshold segmentation method based on 
MHFFCM [147] to L channel converted from the Gaussian smoothed tissue image (σ = 1.6 × 2). 
In principle, given n data points X = +-/01 , it generates an optimal partition by minimizing the 
following objective function: 
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where c, b, ,-., and   denotes the number of groups, the exponential weight factor, the 
membership degree of -  to jth group, and the center of jth group, respectively.  For each L 
channel of tissue image, data points are generated at each intensity level and contain intensity 
and spatial information. For instance, at intensity level i, - = +- , # ,  , ^ , A, ¬ , ¬/  is 
defined where -  and # denote the average horizontal and vertical coordinates, respectively.  
 and ^  are designated as standard deviation of the location of all pixels with the intensity level 
i and frequency of the intensity level i, respectively. ¬  and ¬ represent average and standard 
deviation of the distances from the center of all pixels with the intensity level i, respectively. 
Following the segmentation, in third stage, individual nucleus is identified. Ordering clusters in 
ascending order of the average intensity Ù = +Ù1, Ù, … , Ù¨/, the roundness of the cluster(s) is 
computed as adding new cluster at a time according to the order and identify the union of 
clusters (g*) resulting in the best roundness score. 
å∗ = argmax©∈⋃ Ç vøùIú,å. 
vøùIú,å. = ûℎù_¬äAø,å. + ýøùI_¬äAø,å.2  
where Qhull_ratio and Bound_ratio denote a ratio between the area of a cluster and the areas of 
convex hull and minimum bounding circle of the cluster, respectively. Among the segmented 
epithelial nuclei, those that are round (¬2/2 < 4.0 and vøùIú > 0.7) and relatively 
small (< 45μm) are called regular epithelial nuclei and those that are not regular are designated 
as irregular epithelial nuclei. For stomal nuclei, the same method is applied, and round and 
relatively small nuclei are designated as stromal round nuclei and the rest of them are called 
stromal spindled nuclei. 
7.1.3 Morphological Feature Extraction 
We have segmented eight distinct types of objects inside tissue – epithelium, stroma, lumen, cleft, 
epithelial regular and irregular nuclei, and stromal spindled and round nuclei. For each of these 
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objects, we define a set of feature categories which describe their individual characteristics 
including number, size, shape, and distribution. Also, relational features are defined to describe 
the relationship between different histologic objects; for example, the minimum distance 
between different objects or ratio between the areas of different objects. 
For each of the features defined above, we compute, as did in Chapter 5, two types of 
features: 1) Global feature 2) Local feature. Global features are computed from the entire tissue 
sample to characterize the overall characteristics of the tissue. To compute local features, we 
slide a small window of size wxw (w=12,24,36,48,60μm) throughout the tissue sample, compute 
feature values inside the window, and summarize them by computing their AVG, STD, MIN, 
and/or MAX. Local feature is adopted due to the heterogeneity of cancer. In total, 3,000 features 
are generated for each tissue sample. 
7.2 Chemical Features 
A tissue consists of various cell types, and each cell type contains a number of sub-cellular 
components, i.e., a tissue is heterogeneous. As shown in Chapter 3, the biological variation is, in 
fact, the primary source of variation in a tissue. Similarly, cancer is composed of heterogeneous, 
dynamic multicellular components; as suggested in [91], different subtypes of cancer may 
possess different characteristics and require different bio- or imaging-markers to be identified. 
Due to heterogeneity of intra- and inter-variability in cancer, differences or signatures of cancer 
recurrence and non-recurrence are not apparent. Here, we hypothesize that the signatures reside 
in a part of cells or tissues which are relatively more homogeneous. To prove it, we split tissues 
or cells and seek to find more homogeneous and specific subgroups which are representative of 
cancer recurrence or non-recurrence. In FT-IR imaging, the chemical properties of molecules 
reflected in spectra, and the homogeneity of subgroups in chemistry can be examined through the 
IR spectra. Owning similar IR spectra or spectral patterns means bearing similarity in chemistry. 
In order to find such subgroups, we adopt a frequent pattern mining approach which requires 
transforming a continuous IR spectrum into a discrete format. The process of chemical feature 
extraction is available in Figure 7.1. 
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7.2.1 Discretization 
Each IR metric is independently discretized by adopting equal-width binning, which equally 
divides the entire data range into a number of equal-length bins (Figure 7.1a). A bin simply 
represents an interval in a metric, and a pixel now contains a set of nominal values, which 
represent unique bins (or intervals). Belonging to the same bin, pixels are expected to be more 
homogeneous in chemistry. Each bin or any combination of the bins denotes a different subgroup 
of cells and is designated as a (spectral) pattern. We discretized IR data using 20 bins. Other 
approaches to binning are also applicable. 
7.2.2 Frequent Pattern Mining 
Consider a dataset p = +I1, I, … , I/  that has ßÅ  categorical attributes, and class label  =
+#1, #, … , #/ has ß  classes where #  is the label associated with data I . Each attribute can 
have a number of values, and each pair of an attribute A and a value v (A, v) is mapped to an 
distinct item in r = +ä1, ä, … , ä2/. Subsequently, each datum I can be represented as a set of 
items in r. In the dataset, frequent patterns are the itemsets which occur no less than a user-
specified threshold. In other words, an c-itemset γ, consists of c items from r, is frequent if γ 
occurs no less than |p|  times in a dataset, where   is a user-specified minimum support 
threshold (min_sup) and |p| is the total number of data. The support of a pattern is the number of 
data contains the pattern. Here, a datum I is a pixel in FT-IR imaging, a bin is mapped to an 
item in r, an attribute A is a metric, and two classes – recurrence and non-recurrence – are given 
(Figure 7.1b). Numerous methods are available to efficiently mine frequent patterns. Among 
them, we chose FP-growth [148], which generates the complete set of frequent patterns without 
candidate generation, to mine frequent patterns; however, other methods can be used for the 
same purpose. We set min_sup =0.02. 
7.2.3 Discriminative Patterns 
A huge number of frequent patterns are, in general, generated by frequent pattern mining 
methods, but many of these patterns may be indiscriminative regarding the given class labels, i.e., 
uninformative for the classification [149]. Examining the entire frequent patterns may not be 
time- and space- effective. Hence, it is instructive to eliminate the uninformative patterns prior to 
constructing classification model while retaining the informative ones, called discriminative 
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patterns. To attain the discriminative patterns, we adopt a two-stage pruning method (Figure 
7.1b). In the first stage, the statistical significance of the patterns over the entire dataset is 
examined via log-odds ratio test. In the second stage, Wilcoxon rank-sum test is performed on 
the core-level. Odds ratio measures the association between a pattern and outcomes. The odds of 
each pattern in both recurring cases and non-recurring controls are computed and the natural 
logarithm of their ratio is tested if p-value <0.01, designated as a significant pattern. Computing 
the occurrences of these significant patterns in each core, Wilcoxon rank-sum test provides the 
most discriminative top m patterns (We set m=100). The (normalized) occurrences of these 
patterns for each tissue sample become IR features (Figure 7.1b). Among the IR features, we 
selected the optimal feature set by adopting two-stage feature selection approach as described in 
Chapter 2. 
7.3 Dataset 
In this chapter, we used a set of 5 slides of the outcome-based TMAs constructed by the National 
Institutes of Health-sponsored Cooperative Prostate Cancer Tissue Resource (CPCTR) [150]. 
The tissue samples and clinical data were collected from 16 hospitals affiliated with the Medical 
College of Wisconsin, University of Pittsburgh, New York University, and George Washington 
University. These  TMAs contain up to four tissue core samples from 404 patients who 
underwent prostatectomy. Half of the patients (cases) experienced biochemical recurrence after 
RP and the other half (controls), who have not experienced biochemical recurrence at least 5 
years after RP, matched to the cases based on age at surgery, race, Gleason sum score, pathologic 
stage. Both cases and controls had a PSA nadir and at least 5 serum PSA tests following RP. 
Biochemical recurrence was defined as a single postsurgery PSA level ≥0.4 ng/mL or a single 
PSA level ≥0.2 ng/mL and the next PSA level higher than this level. By the nested case-control 
design, the cohort is enriched by intermediate risk group; ~90% of the patients are grouped into 
an intermediate risk group by D’Amico risk grouping [82]; 268 out of 404 patients have Gleason 
sum 7. This is because many of the high risk subjects who had biochemical recurrence were not 
included since the original cohort of 1,430 subjects did not have an appropriate matched pair 
without a recurrence. Likewise, only a few of the low risk subjects ever had a recurrence. These 
TMAs, hence, are recurrence-enriched and mid-grade dominant, which are unique and 
challenging compared to other studies [27] [28] [30] [29]. The TMA population was divided into 
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two sets, a calibration set of 60 matched pairs (120 subjects), and a validation set of 66 subjects 
where we disregarded the nested case-control design and studied each subject individually. 
Although all participating patients were diagnosed with prostate cancer, some or many of 
their tissue cores do not have enough cancer cells. By pathologic review with the help of IR cell-
type classification, areas representing cancer cells were selected and those tissues with 
insufficient amount of cancer cells (<10% of core) were omitted. Meanwhile, stromal cells in the 
vicinity of cancer cells (within ~40μm) were also selected. From the study of the engineered 
tissue [151], chemical changes were observed within 50-100μm  of tumor by IR imaging; 
however, the density of stromal cells is limited in tissue samples so that restricting stroma 
~40 	μm  away from tumor helps balancing the data. Among 404 patients, we selected only 
subjects who had at least two cores with both epithelial cancer cells and adjacent stroma cells. 
Calibration dataset consists of 60 patient pairs which have 380,685 and 333,167 epithelial 
recurrence and non-recurrence pixels, respectively, (IR epithelium dataset) and 101,576 and 
95,925 stromal recurrence and non-recurrence pixels, respectively (IR stroma dataset). For 
comparison with Kattan nomogram and CAPRA-S score, we selected 82 patients (35 recurrence 
cases and 47 non-recurrence controls), who have no record of neoadjuvant or adjuvant therapy, 
from the calibration dataset regardless of the nested case-control design. In the same way, we 
chose validation dataset of 66 patients (38 recurrence cases and 28 non-recurrence controls) with 
193,620 epithelial recurrence, 133,126 epithelial non-recurrence, 50,745 stromal recurrence, and 
41,130 stromal non-recurrence pixels, respectively. Clinical characteristics of the patient cohort 
are available in Table 1. 
7.4 Classification 
Regarding the nested case-control design of the TMAs, we first attempt to distinguish each pair 
of a recurrence case and non-recurrence control by applying Ranking-SVM [61] (Figure 7.2a). 
Here, Ranking-SVM intended to rank tissue cores of a recurrence case higher than those of a 
non-recurrence control. Provided with the complete rank of the cores from two patients  º1 and 
º, we compute the number of swaps (for º1) as follows: 
yäº,º1; º. = ! ! "^,ä. < ^,7.&
È∈¼w∈¼Õ
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where  is indicator function and Õ  represents a set of cores from a patient º1. Comparing the 
number of swaps for the patients determines a recurrence or non-recurrence, i.e., a patient who 
has smaller number of swaps is designated as recurrence. If tied, the sum of the actual prediction 
values is considered. If the average values are also tied, we randomly break the tie. However, in 
the clinic, we are only given cores from a patient of interest, not a pair of patients. In order to 
predict the outcome of the individual patient, we compute two preference scores for the given 
patient as compared to its matching recurrence and non-recurrence patients via Ranking-SVM. A 
preference score is computed for two patients º1 and º: 
º¬ú^ú¬úVú,º1, º. =
∑ ¬äAå,.∈¼Õ
Ö  
where ¬äAå,•. denotes a rank of •, Õ  represents a set of sample cores from a patient º1,  
denotes an individual core, Ö is a normalization factor, and I ≥ 1. Based on the two scores, we 
predict the probability of recurrence of the patient using a logistic regression model (Figure 7.2b). 
To find the closet matching patients, we measure the similarity between patients as the inverse of 
Euclidean distance between clinical variables – age at surgery, Gleason sum, and pathologic 
stages. Pathologic stages are considered as discrete variables; for pTNM staging, T2a = 0, T2b = 
1, T3a = 2, and T3b = 3; for surgical margin status, extra capsular extension, seminal vesicle 
involvement, and lymph node involvement, no (or negative) = 0 and yes (or positive) = 1. Each 
variable is normalized prior to computing the similarities. 
7.5 Results 
7.5.1 IR Stroma Features Distinguishing Cancer Recurrence 
For the two IR datasets – epithelium and stroma, we extract chemical IR features separately. IR 
dataset was first discretized through equal-width binning (using 20 bins), independently on each 
spectral metric, and a frequent pattern mining method was applied to find frequent patterns from 
both cases and controls. Conducting two statistical tests, namely log-odds ratio test and 
Wilcoxon-rank sum test, the top-100 most discriminative patterns are chosen, and the 
(normalized) occurrences of these patterns for each tissue core become (initial) IR features. Two 
distinct feature sets (IR epithelium and IR stroma) were generated for each tissue core. Applying 
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two-stage feature selection, we obtained the optimal discriminating feature set and built a 
classification model (Ranking-SVM) for each. Performing K-fold cross-validation, we first 
examined the discriminative ability of the IR features on the calibration dataset (K=10). ). The 
dataset was divided into K roughly equal-sized partitions, one partition was left out as the “test 
dataset”, and the union of the remaining K-1 partitions formed “training dataset” where a 
prediction model was trained. This was repeated K times with different choices of the left-out 
partition. From the cross-validation, we observed that IR epithelium feature set was not capable 
of distinguishing cases from controls (AUC ~0.5). IR stroma feature set, however, could 
discriminate recurrence cases from non-recurrence controls with ~70% accuracy (p-value<0.001). 
It should be noted that the decision is made on each pair of the matched patients. To assess the 
ability of IR stroma features to predict the outcome of a single patient, regardless of the nested 
case-control design, we found the closest recurrence and non-recurrence patients from the 
training dataset using clinical variables (age at surgery, Gleason sum, and pathologic stage) and 
computed preference scores against the two matching recurrence and non-recurrence patients. 
Using the preference scores, a logistic regression model predicted the outcome for the single 
patient which is the predicted probability of recurrence (PPR) at 5-year after RP (IR score). The 
correct and incorrect predictions were summarized into a ROC plot and ~0.7 AUC (95% CI, 
0.60-0.79) was achieved. Afterwards Ranking-SVM for patient pair classification and a logistic 
regression model for individual patients were trained on the calibration dataset and tested on the 
validation dataset. As a result, IR score achieved ~0.69 AUC (95% CI, 0.56-0.82) (Figure 7.3b). 
These results indicate that stroma contains chemical signatures for cancer progression. 
Automated methods, combining computational and statistical approaches, are capable of 
recognizing and utilizing the signatures from FT-IR imaging to construct a robust and accurate 
predictive model.  
7.5.2 IR Score Outperformed the Existing Tools in Predicting Outcomes 
We compared the performance of IR score to the two most commonly used clinical tools (Kattan 
nomogram and CAPRA-S score) for predicting outcomes after RP. After excluding patients with 
any type of neoadjuvant therapy, the predicted probability of recurrence by Kattan nomogram 
(Kattan score) and CAPRA-S score were computed in 82 patients (35 recurrence cases and 47 
non-recurrence controls) in the calibration dataset. As shown in Figure 7.3a, IR score (0.71 AUC; 
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0.59-0.82 95% CI) of these 82 patients outperforms both Kattan (0.6 AUC; 0.47-0.72 95% CI) 
and CAPRA-S (0.62 AUC; 0.49-0.74 95% CI) scores. For the validation dataset of 66 patients, 
Kattan (0.44 AUC; 0.29-0.58 95% CI) and CAPRA-S (0.47 AUC; 0.33-0.61 95% CI) scores 
performed far worse than IR score (0.69 AUC; 0.56-0.82 95% CI). The performance of IR score 
in the validation dataset was significantly higher than others (p-value=~0.01), but it was not 
significant in the calibration dataset. We note that the nested case-control design is no longer 
considered for either the calibration or the validation datasets in predicting outcome for an 
individual patient and computing AUCs. In fact, the performance of Kattan and CAPRA-S 
scores was only ~0.5 AUC in this cohort possibly due to the nested case-control design approach 
for initial selection of cases, an approach that enriches the population for biochemical recurrence 
cases, and for intermediate risk for recurrence cases. Interestingly, we found differences in the 
performance of Kattan and CAPRA-S scores for the calibration dataset and the validation dataset. 
This may be attributable to the differences in clinical characteristics of the patients (Table 7.1). 
For instance, in the validation dataset, differences in age and PSA level between recurrence cases 
and non-recurrence controls are smaller compared to those in the calibration dataset. More 
recurrence cases than non-recurrence controls (17 recurrence cases and 6 non-recurrence controls) 
with lower Gleason sum (≤6) exist in the validation dataset. However, the performance of IR 
score was consistent 
Furthermore, the distribution of the patients according to the scores by each tool was 
compared (Figure 7.4). By Kattan score, 64-89% of both recurrence cases and non-recurrence 
controls had ≤30% PPR. Only a small fraction of recurrence cases (6% of the calibration dataset, 
7% of the validation dataset) was recognized as having higher PPR (≥70%). A strong correlation 
between recurrence cases and non-recurrence controls by Kattan score was observed (Spearman 
r = 0.83 for 82 patients in the calibration dataset; r = 0.9 for the validation dataset). For CAPRA-
S score, a lower risk category (score 0-2) contains 43-53% and 37-42% of non-recurrence 
controls and recurrence cases, respectively. ~14% of recurrence cases as well as 9-18% of non-
recurrence controls were grouped into a higher risk category (score≥6). The correlation between 
recurrence cases and non-recurrence controls was also high (Spearman r = 0.73 for 82 patients in 
the calibration dataset; r = 0.66 for the validation dataset). Hence, for the patient population in 
this study, the capability of the two existing tools in identifying patients at higher or lower risk is 
very limited. By IR score, on the other hand, ~3-fold more non-recurrence controls (43-50% and 
93 
 
11-21% of non-recurrence controls and recurrence cases) had lower PPR (≤30%), respectively. 
2- to 4-fold more recurrence cases (13-14% of non-recurrence controls and 40-42% of recurrence 
cases) showed higher PPR (≥70% ).  IR score is inversely correlated between cases and controls 
(Spearman r = -0.59 for 82 patients in the calibration dataset; r = -0.28 for the validation dataset). 
These imply that the patients, grouped into an intermediate (or lower) risk group by the 
conventional tools, can be further stratified by IR score whereas both Kattan and CAPRA-S 
scores were not contributory.  
7.5.3 IR Score is an Independent Predictor of Cancer Recurrence 
The relationship between IR score and recurrence of cancer was measured by estimating odds 
ratio. We fitted a logistic regression model using IR score and other clinical variables (age at 
surgery, Gleason grade, pathologic stage, and PSA level) as covariates. IR score was added as 
either continuous or categorical variables. As a categorical variable, patients were assigned to 
quartiles by IR score. For both types, a significant inverse association between IR score with 
cancer recurrence was observed (p-value<0.001 as a continuous variable and ~21-fold 
differences between the lowest quartile and the highest quartile as a categorical variable) (Table 
7.2). A moderate linear trend of odds ratios was observed across quartiles (p-value <0.05). From 
Kattan and CAPRA-S scores, 2- to 6-fold differences were observed between the extreme 
quartiles. Since the odds ratio estimates of IR score in the logistic regression model were 
adjusted for other clinical variables, the association between IR score and cancer recurrence is 
independent from these variables.  
7.5.4 Addition of the Existing Tools to IR score 
As shown above, IR score is related to cancer recurrence independently from several clinical 
variables, on which many existing tools rely upon. Here, we examine the interaction between IR 
score and the other two scores (Kattan and CAPRA-S). IR score is combined with Kattan and 
CAPRA-S scores as follows: 
G¨ = -rv¨ + #¨ 
G¨  and rv¨  denote combined score and IR score, respectively. - and # are weights for 
each score ,0 ≤ -, # ≤ 1. .  ¨  is either Kattan score or CAPRA-S score. As changing 
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weights - and # from 0 to 1, the combined score G¨ is summarized into a ROC curve and 
AUC was computed. By adding IR score, the performance of both Kattan and CAPRA-S scores 
improved but the improvement was not statistically significant (Figure 7.5). Combined with the 
IR score, the AUC of Kattan score reached 0.75 and 0.69 in the calibration and validation 
datasets, respectively, whereas 0.60 and 0.44 AUCs were obtained without the IR score in the 
calibration and validation datasets, respectively. Likewise, the AUC of CAPRA-S score 
increased from 0.62 to 0.75 and 0.47 to 0.70 in the calibration and validation datasets, 
respectively, as combined with the IR score. Also, the combined score only marginally improved 
the performance of IR score alone. Since Kattan and CAPRA-S scores did not perform well, it is 
not surprising that the combined score with IR score was not able to significantly improve upon 
IR score alone. Another explanation of why a combination of Kattan nomogram or CAPRA-S 
score methods with IR scores was not expected to improve much upon IR scores alone is that 
some of the clinical variables were already taken into account when computing IR scores. As a 
result, the synergy between IR score and the two scores was not substantial. One way to utilize 
IR score is to add it to the existing tools as an additional factor and to improve the utility of the 
tools, especially for the patients who have similar characteristic with the patient cohort in this 
study. Nonetheless, thorough and extensive study should be conducted to validate the effect and 
usefulness of IR score to the existing tools, preferably in a cohort where these tools have already 
shown stronger predictive value. 
7.5.5 IR Stroma Features Correspond to Specific Functions in Stroma 
The prediction model for patient pairs (Ranking-SVM) were built on the 45 IR stroma features of 
length 3 or 4. The features comprise 34 metrics (Figure 7.6). Examining the metrics, two 
prominent spectral regions were recognized. The peaks in 3000-3600cm-1 were present in all of 
the features, which is related to N-H stretching vibration in proteins or O-H stretching vibration 
[152] [153]. About half of the features were related to the peaks in 990-1132cm-1, which include 
C-O stretching vibration of 1042cm-1 due to oligosaccharide [154]. Other metrics are associated 
with nucleic acids, glycogen, collagen, amino acids, fatty acids, or proteins. The complete list of 
the metrics is available in Table 7.3. Pixels or areas containing any of the optimal discriminating 
IR stromal features are marked on tissue cores (IR images) and compared to their corresponding 
H&E images (Figure 7.7). Due to the differences in imaging techniques and distance between the 
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serial sections used for each imaging, the exact mapping of the IR features on the corresponding 
H&E images was unfeasible. However, the stromal features appear, by and large, in the regions 
where reactive stoma is present. More specifically, loose or myxoid stroma and fibroblasts are 
often found. Stromal reaction (or desmoplasia), which occurs in most solid human cancers [155] 
[156] [157] [158], contains increased number of fibroblast and myofibroblasts and modifies 
extracellular matrix compositions. We also note that the discriminating features are frequently 
present next to periacinar retraction (clefting), a separation of the gland from the adjacent stroma 
[159] that has been associated with cancer recurrence [146]. Examining the metrics, features, and 
images, the IR stromal features may be related to the molecules pertaining to (myo)fibroblasts, 
extracellular matrix composition or retraction clefting; for instance, chondroitin sulfate, known 
to be associated with prostate cancer progression [160]. However, the specific molecules or 
chemical/biological causes relevant to the IR features cannot be identified. In order to understand 
the precise biological and chemical properties of the features and the corresponding areas, the 
subsequent experiments such as immunohistochemistry, proteomics, or glycomics should be 
conducted. Moreover, obtaining higher spatial resolution IR imaging [119] could improve the 
recognition of the features yielding a finer classification model and, in turn, achieve better 
discrimination between recurrence cases and non-recurrence controls. The ultimate goal of these 
follow-up studies will be to study the predictive value of IR stromal features in pre-operative 
settings, in order to avoid unnecessary treatment. 
7.6 Conclusion 
We have presented an automated prediction tool for prostate cancer outcome. The prediction is 
crucial in patient care and treatment. FT-IR imaging is adopted to discover a set of spectral 
features characterizing cancer progression from epithelium and stroma separately in tissue 
samples. To avoid the effect of the external factors, recurrence cases and non-recurrence controls 
were matched on several clinical variables. Not epithelium features but stroma features from FT-
IR imaging could distinguish recurrence cases from non-recurrence controls and are superior to 
the commonly used tools. The findings, hence, clearly prove the utility of FT-IR imaging for 
outcome prediction, i.e., prostate pathology. Combined with computational and statistical 
methods, it uncovered the hidden patterns or features in stroma, which can be related to specific 
functions or activities in tissue and be subjects of the subsequent studies to reveal their detailed 
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chemical/ biological meanings. Although unidentified, signatures of cancer recurrence may exist 
in epithelium. It is due to interaction between epithelium and stroma, not an independent 
mechanism by one element. Hence, the analysis considering both epithelium and stroma together 
may be able to discover the epithelium features as well as new stroma features. This will 
facilitate broader and deeper understanding of the disease and interactions between epithelium 
and stroma. We also note that this approach is generic and can be applied to other types of 
disease and analytical techniques.  
7.7 Figures and Tables 
 
Figure 7.1: Overview of chemical feature extraction. Given an IR image, (a) cell-types 
(Epithelium and Stroma) are identified by IR imaging and, by pathologic review, cancer cells 
(red; C-Epithelium) and adjacent stroma (blue; C-Stroma) cells are selected and discretized. 
Upon discretization, pixels in tissue are marked with different colors according to the bins they 
belong. (b) Applying frequent pattern mining and statistical tests, IR features are extracted. C-
Epithelium and C-Stroma denote the selected cancerous epithelium and stroma next to it, 
respectively. Black and white bars denote 100µm and 500µm, respectively. 
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Figure 7.2: Prediction models for outcome. Using morphological or chemical features, 
prediction models for (a) patient pairs and (b) an individual patient are formed and predictions 
are made. (a) Ranking-SVM provides prediction on patient pairs. (b) Logistic regression model 
predicts outcome of an individual patient. 
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Figure 7.3: Performance of outcome prediction. Outcome prediction of three models – 
CAPRA-S (black), Kattan nomogram (blue), and IR (red) – on (a) the calibration dataset and (b) 
the validation dataset. AUCs and 95% confidence intervals in parentheses are shown on the 
plots. 
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Figure 7.4: Score distribution. Distribution of the recurrence cases (red) and non-recurrence 
controls (black) by (a)(d) Kattan nomogram (b)(e) CAPRA-S (c)(f) IR. Distributions in (a)(b)(c) 
the calibration dataset and (d)(e)(f) the validation dataset are plotted. PPR represents the 
predicted probability of recurrence. 
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Figure 7.5: Combination of IR and other tools. IR score is combined with (a)(d) Kattan score 
as well as (b)(e) CAPRA-S score from (a)(d) the calibration dataset and (b)(e) the validation 
dataset. (c)(f) Best ROC curves of the combinations, as outperforming IR score alone, are 
depicted. Increasing a weight of IR score (grey line), the performance of the combinations with 
both Kattan and CAPRA-S scores improves. Raising weights of Kattan (black line) and CAPRA-
S (blue line) scores, the combination with IR score slightly improves the performance of IR score 
alone.  
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Figure 7.6: IR feature map. Metrics associated with the IR stroma features are shown. Each 
row represents an IR feature. Each column denotes a metric. Metrics are ordered as presented in 
Table 7.3. Bins are marked with different colors. 
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Figure 7.7: Comparison of IR and H&E images. IR stroma features (red rectangles) and their 
corresponding areas (red circles) are marked on IR and H&E images, respectively. (a)(c)(e) 
Recurrence images and (b)(d)(f) non-recurrence images. C-Stroma represents stroma cells 
adjacent to cancer cells. Black scale bars denote 100µm. IR features are related to (a)(b)(e)(f) 
loose or myxoid stroma, (b)(c)(d)(e)(f) fibroblasts, and (a)(d)(e)(f) retraction clefting. 
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Table 7.1: Clinical characteristics of patient cohort in TMAs. 
  Calibration (n=120) Calibration (n=82) Validation (n=66) 
  
Cases  
(n=60) 
Controls 
(n=60) 
Cases 
(n=35) 
Controls 
(n=47) 
Cases 
(n=38) 
Controls 
(n=28) 
Age at surgery, 
mean (SD) 
61.6 (7.1) 62.9 (6.5) 62.2 (7.1) 63.1 (6.7) 63.1 (7.1) 63.8 (5.3) 
Race, n 
(%) 
White 51 (85) 51 (85) 30 (85.7) 40 (85.1) 33 (86.8) 25 (89.3) 
African 
American 
9 (15) 9 (15) 5 (14.3) 7 (14.9) 4 (10.5) 3 (10.7) 
Other     1 (2.6)  
Gleason 
sum,  
n (%) 
≤6 12 (20) 12 (20) 7 (20) 10 (21.3) 17 (44.7) 6 (21.4) 
7(3+4) 35 (58.3) 35 (58.3) 21 (60) 28 (59.6) 16 (42.1) 15 (53.6) 
7(4+3) 7 (11.7) 7 (11.7) 6 (17.1) 6 (12.8) 4 (10.5) 3 (10.7) 
≥8 6 (10) 6 (10) 1 (2.9) 3 (6.4) 1 (2.6) 4 (14.3) 
Pathologic
al stage,  
n (%) 
T2a 7 (11.7) 7 (11.7) 4 (11.4) 7 (14.9) 2 (5.3) 2 (7.1) 
T2b 33 (55) 33 (55) 18 (51.4) 30 (63.8) 26 (68.4) 15 (53.6) 
T3a 19 (31.7) 19 (31.7) 13 (37.1) 10 (21.3) 10 (26.3) 11 (39.3) 
T3b 1 (1.7) 1 (1.7)     
Serum PSA ng/mL, 
mean (SD) 
10.6 (8.7) 8.6 (6.0) 
10.4 
(10.2) 
8.7 (6.1) 9.5 (7.2) 8.5 (4.8) 
Month to recurrence, 
mean (SD) 
38.6 
(29.0) 
 
44.5 
(33.1) 
 
36.6 
(28.7) 
 
The patient characteristics are shown for the calibration dataset of 60 pairs and 82 patients 
without neoadjuvant or adjuvant therapy and the validation dataset of 66 patients. n and SD 
denote number and standard deviation, respectively. 
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Table 7.2: Odds ratios for cancer recurrence by quartiles of IR score. 
Quartile 1 (low) 2 3 4 (high) P trend 
IR 
OR (95% CI) 
1 
0.510 
(0.130-1.907) 
0.304 
(0.071-1.178) 
0.047 
(0.006-0.241) 
0.025 
CAPRA-S 
OR (95% CI) 
0.163 
(0.025-0.896) 
0.530 
(0.079-3.285) 
0.205 
(0.035-1.036) 
1 0.146 
KATTAN 
OR (95% CI) 
1 
0.734 
(0.176-3.015) 
0.457 
(0.096-2.095) 
0.549 
(0.073-3.898) 
0.065 
OR and CI denote odds ratio and confidence interval, respectively 
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Table 7.3: Description of the selected metrics. 
Metric Type Numerator Position  
or Region (cm-1) 
Denominator Position  
or Region (cm-1) 
Assignment 
Absorbance Ratio 3088 1400 O-H stretching [152], 
N-H stretching, 
Protein [153] 
 
Absorbance Ratio 3088 1450 
Absorbance Ratio 3288 1400 
Absorbance Ratio 3288 1544 
Absorbance Ratio 3288 1652 
Peak-to-Area Ratio 3288 1504–1586 
Area-to-Peak Ratio 3030–3600 1544 
Area-to-Area Ratio 3030–3600 1592–1738 
Center of Gravity 3200–3400  
Center of Gravity 3030–3600  
Absorbance Ratio 1042 1450 C-O stretching, 
Oligosaccharide [154] Absorbance Ratio 1042 1544 
Absorbance Ratio 1042 1652 
Area-to-Peak Ratio 992–1110 1544 
Center of Gravity 998–1052  
Center of Gravity 998–1132  
Absorbance Ratio 966 1544 C-O stretching,  
Nucleic acid [161] Peak-to-Area Ratio 966 1504–1586 
Absorbance Ratio 1080 1450 Symmetry phosphate 
stretching, Nucleic acid [162], 
Glycogen [163] 
Absorbance Ratio 1080 1652 
Peak-to-Area Ratio 1170 1504–1586 Nucleic acid [164] 
Area-to-Peak Ratio 1150–1176 1544 
Absorbance Ratio 1336 1080 CH2 wagging [165], 
Collagen [166] Absorbance Ratio 1334 1652 
Peak-to-Area Ratio 1336 1504–1586 
Area-to-Peak Ratio 1326–1348 1544 
Absorbance Ratio 1388 1652 COO- symmetric stretching, 
fatty acids and amino acids 
[167] 
Peak-to-Area Ratio 1390 1504–1586 
Center of Gravity 1366–1426  
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Table 7.3 (cont.)    
Absorbance Ratio 1462 1400 CH2 scissoring [168], CH2 
bending, amino acids [169] Absorbance Ratio 1452 1652 
Area-to-Peak Ratio 1424–1474 1544 
Peak-to-Area Ratio 1564 1504–1586 Amide II [170] 
Peak-to-Area Ratio 1652 1504–1586 Amide I [171] 
Metric definitions and assignments of the numerator bands are provided. The assignment of 
denominator bands, which do not present among the numerator bands, is 1400cm-1 (COO- group, 
fatty acids and amino acids) [172], 1450cm-1 (Methylene deformation) [172], and 1544cm-1 
(Amide II) [173]. 
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Chapter 8  
Conclusion 
 
 
Precise cancer diagnosis and prognosis are of great importance in managing disease and patients. 
The current pathology services largely rely upon ad hoc manual decisions. Alternate 
computational and imaging techniques and tools are promising, but rarely have these methods 
gained widespread acceptance. In this thesis, we have developed automated and computational 
tools for prostate cancer pathology by utilizing FT-IR imaging. This not only proves the 
capability of FT-IR imaging in aiding cancer pathology but also relates it to the conventional 
pathologic methods. We also note that the conventional pathologic methods can benefit from FT-
IR imaging. Further, establishing a statistical framework for the imaging ensures the 
development of robust and rigorous methods. The specific contributions are following: 
• We have presented ANOVA models for FT-IR imaging data from a large population and 
identified the main sources of variation. Adopting the models, the ability of FT-IR 
imaging to a particular problem or setting can be statistically and systematically 
examined while considering its structure or design. The thorough understanding of the 
design components ensures developing robust applications as well as improved protocol 
designs. This has not been of a great interest in spectroscopy community. 
• We have developed an accurate, robust and automated cancer detection method from FT-
IR imaging and brightfield microscopy imaging. Combining the two complementary 
imaging techniques, we effectively and efficiently reduced the effect of staining 
variability in tissue, which has been one of the major concerns in restricting the 
appreciation of the automated methods built upon microscopy imaging. FT-IR imaging, 
hence, not only helps improving cancer diagnosis but also improves the utility of 
microscopy imaging as well as the automated methods relying upon it. Notably, our 
approach does not require modifying the microscopic images, and thereby the impact of 
the FT-IR imaging will be prompt and efficient in any settings. 
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• A time- and cost-effective information management and decision-support system for 
cancer pathology has been developed. Provided with relevant samples and their clinical 
and pathologic information from the previous records, the manual decisions will be more 
consistent and reliable, i.e., reducing intra- and inter-variability in grading. The system is, 
in fact, independent of the techniques or information incorporated in it. That is, any 
imaging or analytical techniques can be incorporated into the system as long as they 
contain valid information of tissue. Accordingly, the system will enhance the usability of 
the other techniques and the addition of others will improve the capability of the system. 
• A novel automated outcome prediction tool has been developed using FT-IR imaging. 
Chemical stromal features are detected and utilized to build the prediction models. The 
chemical features are independent of the conventional parameters of patients and 
powerful in discriminating recurrence cases from non-recurrence controls. Adopting 
CPCTR approach, the dataset under consideration is enriched for recurrence cases and 
mid-grade subjects where the commonly used tools are ineffectual.  The method, hence, 
tackles challenging and demanding but unresolved subjects yet. Moreover, the further 
studies on the suggested molecules in stroma and periacinar retraction will deepen and 
widen our understanding of the disease.  
A tremendous amount of effort has been made to improve cancer pathology today in many 
directions. Among them, imaging techniques provide golden opportunities in greatly advancing 
the clinical practice and cancer research. The importance of the imaging techniques has been 
remarkably recognized by researchers and practitioners. Various types of imaging techniques 
exist and deliver different sorts of information of disease and patients. Combining different axes 
of images or information can help in developing accurate and robust tools and understanding the 
disease. Now the key question to answer is how to extract precise and sufficient information 
from the images and to utilize it in an efficient and effective way. Revealing the critical 
information and integrating it with the conventional methods and knowledge will definitely lead 
to improved cancer pathology. 
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Appendix A 
Analysis of Variance 
 
 
Table A.1: Symbols in ANOVA models. 
Symbol Description  
# IR absorption of a pixel (y = 1,… , ) at a spectral metric of interest  
 Overall mean of IR absorption in data  
C Effect of ith array (A = 1,… , ~)  
	 Effect of jth patient (m = 1,… , )  
N Effect of kth core ( = 1,… , )  
* Effect of lth histologic class ( = 1,… , )  
2 Effect of mth subcellular component ( = 1,… , 2)  
6 Measurement error  

 Residual error  
C*  Interaction effect between ith array and lth histologic class  
	* Interaction effect between jth patient and lth histologic class  
N*  Interaction effect between kth core and lth histologic class  
N2 Interaction effect between kth core and mth subcellular component  
	,. Effect of jth patient within ith array  
N,. Effect of kth core within jth patient  
N",.& Effect of kth core within jth patient within ith array  
	*,. Interaction effect between jth patient within ith array and lth histologic class  
N*,. Interaction effect between kth core within jth patient and lth histologic class  
N*",.& Interaction effect between kth core within jth patient within ith array and lth 
histologic class 
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Table A.1 (cont.) 
  Total variance in data  
~ Variation due to differences among arrays  
 Variation due to differences among patients  
,~.  Variation due to differences among patients; patients are nested in arrays  
 Variation due to differences among cores  
,.  Variation due to differences among cores; cores are nested in patients  
",~.&  
Variation due to differences among cores; cores are nested in patients, and 
patients are nested in arrays 
 
 Variation due to differences among histology classes  
 Variation due to differences among sub-cellular components  
e  Variation due to measurement error  
 Variation due to residual error  
~  Variation due to interaction between array and histology class effects  
  Variation due to interaction between patient and histology class effects  
,~.  
Variation due to interaction between patient and histology class effects; patients 
are nested in arrays 
 
",~.&  
Variation due to interaction between core and histology class effects; cores are 
nested in patients 
 
",~.&  
Variation due to interaction between core and histology class effects; cores are 
nested in patients, and patients are nested in arrays 
 
  Variation due to interaction between core and sub-cellular component effects  
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Table A.2: ANOVA table for between-histologic class model.  
SS, df, MS, and EMS denote sum of square, degrees of freedom, mean square, and expected 
mean squares, respectively. MS is computed as SS divided by df. A(B) denote that factor A is 
nested within factor B. * indicates an interaction effect. #x , #$ and 6 represent the true signal, 
average of ith element, and measurement noise, respectively. 
 
Source SS df F-statistic EMS 
Array 
 
∑ ,#$ − .   
~ − 1 
áo~
áo,~. 
e +  +
",~.& +
,~. +
~  
Patient(Array) 
 
∑ "#$,. − #$&,   
~" − 1& 
áo,~.
áo",~.& 
e +  +
",~.& +
,~.   
Core 
(Patient(Array)) 
  
∑ M#$",.& − #$,.P

,,   
~" − 1& 
áo,~.
áo  
e +  + ",~.&   
Histologic class 
~  
∑ ,#$ − .   
 − 1 
áo
áo~∗  
e +  + ",~.& +
 + ~ +
~  
Array 
*Histologic class 
  
∑ ,#$ − #$ − #$ + .,   
,~ − 1., − 1. 
áo~∗
áo,~.∗  
e +  + ",~.& +
 + ~   
Patient(Array) 
*Histologic class 
  
∑ "#$,. − #$,. − #$ +,,
#$&  
~" − 1&, − 1. 
áo,~.∗
áo",~.&∗ 
e +  + ",~.& +
   
Core 
(Patient(Array)) 
*Histologic class 
 ∑ M#$",.& −,,,
#$",.& − #$,. + #$,.P

  
~" − 1&, − 1. 
áo",~.&∗
áo  
e +  + ",~.&   
Residual error ∑ M#x − #$",.&P

,,,,x   ~" − 1&    
Measurement 
error 
∑ 6,,,,x     e   
Total ∑ "#x + 6 − &,,,,x   ~ − 1  
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Table A.3: ANOVA table for within-array model.  
SS, df, MS, and EMS denote sum of square, degrees of freedom, mean square, and expected 
mean squares, respectively. MS is computed as SS divided by df. A(B) denote that factor A is 
nested within factor B. * indicates an interaction effect. #x , #$ and 6 represent the true signal, 
average of ith element, and measurement noise, respectively. 
  
Source SS df F-statistic EMS 
Patient  !"#$ − &


  − 1 
áo
áo,. 
 
e +  + ,.
+  
Core(Patient)  !"#$,. − #$&

,
 " − 1& 
áo
áo  e
 +  + ,.  
Histologic class  !,#$ − .

  − 1 
áo
áo∗  
e +  + ,.
+ 
+  
Patient 
*Histologic class 
 !"#$ − #$ − #$ + &
,
 ~" − 1&, − 1. 
áo∗
áo,.∗ 
e +  + ,.
+   
Core(Patient) 
*Histologic class 
 !"#$,. − #$,. − #$ + #$&
,,
 " − 1&, − 1. 
áo,.∗
áo  e
 +  + ,.  
Residual error ! "#x − #$,.&

,,,x
 " − 1&   
Measurement 
error 
! 6
,,,x
 
  e  
Total ! "#x + 6 − &

,,,x
  − 1  
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Table A.4: ANOVA table for no-histologic class model.  
SS, df, MS, and EMS denote sum of square, degrees of freedom, mean square, and expected 
mean squares, respectively. MS is computed as SS divided by df. A(B) denote that factor A is 
nested within factor B. #x , #$  and 6 represent the true signal, average of ith element, and 
measurement noise, respectively. 
  
Source SS df F-statistic EMS 
Array  !,#$ − .

 ~ − 1 
áo~
áo,~. 
e +  + ",~.& +
,~. + ~  
Patient(Array)  !"#$,. − #$&

,
 ~" − 1& 
áo,~.
áo",~.& 
e +  + ",~.& +
,~.   
Core(Patient(Array))  ! M#$",.& − #$,.P

,,
 ~" − 1& 
áo,~.
áo  
e +  + ",~.&   
Residual error ! M#x − #$",.&P

,,,x
 ~" − 1&   
Measurement error ! 6
,,,x
 
  e  
Total ! "#x + 6 − &

,,,x
 ~ − 1  
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Table A.5: ANOVA table for within-histologic class model.  
SS, df, MS, and EMS denote sum of square, degrees of freedom, mean square, and expected 
mean squares, respectively. MS is computed as SS divided by df. * indicates an interaction effect. 
#x , #$  and 6  represent the true signal, average of ith element, and measurement noise, 
respectively. 
  
Source SS df F-statistic EMS 
Core  !,#$ − .

  − 1 
áo
áo∗ 
e +  + 
+  
Subcellular component  !,#$2 − .
2
  − 1 
áo
áo∗ 
e +  + 
+  
Core 
*Subcellular component 
 !,#$2 − #$ − #$2
,2
+ . 
" − 1&" − 1& 
áo∗
áo  e
 +  +   
Residual error ! ,#2x − #$2.
,2,x
 " − 1&   
Measurement error ! 6
,2,x
 
  e  
Total ! ,#2x + 6 − .
,2,x
  − 1  
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Table A.6: ANOVA table for no-subcellular component model.  
SS, df, MS, and EMS denote sum of square, degrees of freedom, mean square, and expected 
mean squares, respectively. MS is computed as SS divided by df. #x, #$ and 6 represent the 
true signal, average of ith element, and measurement noise, respectively. 
  
Source SS df F-statistic EMS 
Core  !,#$ − .

  − 1 áoáo  e
 +  +  
Residual error !,#x − #$.
,x
 " − 1&   
Measurement error ! 6
,x
 
  e  
Total !,#x + 6 − .
,x
  − 1  
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Table A.7: Description of 93 spectral metrics. 
Metric 
Type 
Num.  
(cm-1) 
Denom. 
(cm-1) Hist. Sub. Bayes Array Assignment 
1 1034 1544 10 38 ●*  Collagen[174] 
1 1042 1544 7 46 ●*  C-O stretching[154] 
1 966 1544 30 49 ●  Nucleic acid, C-O deoxyribose, C-C[161] 
1 1062 1544 2 26 ●*  Ribose/dexoyribse C-O stretching[175] 
1 1080 1544 1 29 ●*  Nucleic acid[162], symmetric phosphate stretching [163] 
1 1104 1544 5 23   Symmetric P-O-C stretching[161] 
1 1114 1544 8 30 ●*  Nucleic acid[176] 
1 1034 1062 57 59 ●  Collagen[174] 
1 1160 1544 36 16   C-O stretching[163] 
1 1164 1080 33 15 ●  C-O stretching[177] 
1 1162 1168 75 73   Stretching modes of the C-OH groups of serine, threonine, and tyrosine residuals of cellular proteins[178] 
1 1206 1544 17 1   Amide III[179], collagen[178] 
1 1236 1544 25 3 ●  Amide III, asymmetric phosphodiester stretching, mainly from 
nucleic acids[180] 
1 1280 1544 88 10  17 Amide III[179], collagen[181] 
1 1206 1544 16 6   Amide III[179], collagen[178] 
1 1226 1544 12 4   Nucleic acids, asymmetric phosphate[161] 
1 1278 1544 38 28  12 Amide III, vibrational modes of collagen[180] 
1 1226 1236 11 88   Nucleic acids, asymmetric phosphate[161] 
1 1312 1544 84 9  19 Amide III band components of proteins[181] 
1 1338 1544 45 18   CH2 wagging[165] 
1 1370 1544 23 52   C-O stretching, C-H deformation, N-H deformation[161] 
1 1388 1544 89 33   COO- symmetric stretching vibration of amino acid side chains 
and fatty acids[167] 
1 1402 1544 51 51  18 Asymmetric CH3 bending of methyl groups of protein[181], C-N 
stretching, N-H deformation, C-H deformation[161] 
1 1450 1544 66 50 ●  Methylene deformation in biomolecules[172] 
1 1462 1544 43 19  9 CH2 scissoring[168] 
1 1388 1400 37 58 ●  COO- symmetric stretching vibration of amino acid side chains 
and fatty acids[167] 
1 1388 1450 70 20   COO- symmetric stretching vibration of amino acid side chains 
and fatty acids[167] 
1 1388 1460 49 13  13 COO- symmetric stretching vibration of amino acid side chains 
and fatty acids[167] 
1 1402 1450 78 27  16 Asymmetric CH3 bending of methyl groups of protein[181], C-N 
stretching, N-H deformation, C-H deformation[161] 
1 1042 1450 9 40   C-O stretching[154] 
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Table A.7 (cont.) 
Metric 
Type 
Num.  
(cm-1) 
Denom. 
(cm-1) Hist. Sub. Bayes Array Assignment 
1 1082 1450 6 42   Collagen[182], phosphate stretching[177] 
1 1236 1450 14 8   Amide III, asymmetric phosphodiester stretching, mainly from 
nucleic acids[180] 
1 1534 1654 76 36   Amide II[183] 
1 1564 1544 40 24  15 Amide II[170] 
1 1654 1544 61 41 ●  Amide I[168] 
1 1640 1544 18 54   Amide I band of protein and H-O-H deformation vibration of 
water[184] 
1 1650 1544 56 47   Amide I[172] 
1 1640 1654 60 76   Amide I band of protein and H-O-H deformation vibration of 
water[184] 
1 1650 1654 81 87   Amide I[172] 
1 1658 1544 63 35   C=O, C=C uracil, NH2 guanine[161] 
1 1724 1544 65 60   ? (1725-1745 cm
-1
, C=O stretching band mode of fatty acid ester 
[185]) 
1 1534 1654 77 37   Amide II[183] 
1 1082 1654 4 39   Collagen[182], phosphate stretching[177] 
1 1236 1654 34 11   Amide III, Asymmetric phosphodiester stretching, mainly from 
nucleic acids[180] 
1 1388 1654 71 21   COO- symmetric stretching vibration of amino acid side chains 
and fatty acids[167] 
1 1402 1654 46 34   Asymmetric CH3 bending of methyl groups of protein[181], C-N 
stretching, N-H deformation, C-H deformation[161] 
1 1450 1654 62 77   Methylene deformation in biomolecules[172] 
1 1462 1654 44 25  10 CH2 scissoring[168] 
1 3204 1544 29 45   O-H stretching[152] 
1 3208 1544 26 55   O-H stretching[152] 
1 3292 1544 91 53 ●  N-H stretching[153] 
1 3430 1544 93 22   N-H stretching bands of mainly trans-ordered substructures[180] 
1 3084 1654 48 62   C-H stretching[152] 
1 3208 1654 41 93   O-H stretching[152] 
1 3292 1654 90 90   N-H stretching[153] 
1 3430 1654 86 32   N-H stretching bands of mainly trans-ordered substructures[180] 
1 3084 1450 24 70   C-H stretching[152] 
1 3208 1450 27 91   O-H stretching[152] 
1 3292 1450 64 89   N-H stretching[153] 
1 3430 1450 69 43   N-H stretching bands of mainly trans-ordered substructures[180] 
1 3084 1400 72 79  3 C-H stretching[152] 
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Table A.7 (cont.) 
Metric 
Type 
Num.  
(cm-1) 
Denom. 
(cm-1) Hist. Sub. Bayes Array Assignment 
1 3208 1400 74 81  2 O-H stretching[152] 
1 3292 1400 79 80  1 N-H stretching[153] 
1 3430 1400 80 78  4 N-H stretching bands of mainly trans-ordered substructures[180] 
1 3084 1080 59 84  6 C-H stretching[152] 
1 3208 1080 58 85  5 O-H stretching[152] 
1 3292 1080 53 82  7 N-H stretching[153] 
1 3430 1080 55 83  8 N-H stretching bands of mainly trans-ordered substructures[180] 
 
Lower 
Limit 
(cm-1) 
Upper 
Limit 
(cm-1) 
Hist. Sub. Bayes Array Assignment 
2 946 982 15 7   Nucleic acid, C-O deoxyribose, C-C[161] 
2 982 1140 3 92   
Collagen[174],[182], C-O stretching[154], ribose/dexoyribse C-O 
stretching[175], nucleic acid[162],[176], phosphate 
stretching[163],[177], symmetric P-O-C stretching[161] 
2 1140 1180 28 12   
C-O stretching[163],[177], stretching modes of the C-OH groups 
of serine, threonine, and tyrosine residuals of cellular 
proteins[178] 
2 1184 1294 21 2   Amide III[179]
,[180], collagen[178],[181], asymmetric 
phosphate[161],[180], vibrational modes of collagen[180] 
2 1296 1326 85 5  14 Amide III band components of proteins[181] 
2 1326 1356 35 17   CH2 wagging[165] 
2 1320 1356 50 14   CH2 wagging[165] 
2 1356 1422 83 44   
C-O stretching, C-N stretching, C-H deformation, N-H 
deformation[161], COO- symmetric stretching vibration of amino 
acid side chains and fatty acids[167], asymmetric CH3 bending of 
methyl groups of protein[181] 
2 1422 1478 54 56   Methylene deformation in biomolecules[172], CH2 scissoring[168] 
2 3000 3140 20 57   C-H stretching[152] 
2 3000 3682 67 31   C-H stretching, O-H stretching[152], N-H stretching[180],[153] 
2 1476 1584 50 86   Amide II[183],[170] 
2 1584 1768 22 48   
Amide I[172],[168] band of protein and H-O-H deformation 
vibration of water[184], C=O, C=C uracil, NH2 guanine[161], 
C=O stretching band mode of fatty acid ester[185] 
3 996 1050 87 67   Collagen[174], C-O stretching[154] 
3 1050 1100 82 65   
Ribose/dexoyribse C-O stretching[175], Nucleic acid[162], 
Symmetric phosphate stretching[163], Collagen[182], phosphate 
stretching[177] 
3 982 1140 92 61   
Collagen[174],[182], C-O stretching[154], ribose/dexoyribse C-O 
stretching[175], nucleic acid[162],[176], phosphate 
stretching[163],[177], symmetric P-O-C stretching[161] 
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Table A.7 (cont.) 
 
Lower 
Limit 
(cm-1) 
Upper 
Limit 
(cm-1) 
Hist. Sub. Bayes Array Assignment 
3 1184 1218 73 75   Amide III[179], collagen[178] 
3 1184 1296 13 74 ●*  
Amide III[179],[180], collagen[178],[181], nucleic acids, 
asymmetric phosphate[161], asymmetric phosphodiester 
stretching, mainly from nucleic acids[180], vibrational modes of 
collagen[180] 
3 1218 1296 19 71   
Amide III[179],[180], collagen[180],[181], nucleic acids, 
asymmetric phosphate[161], asymmetric phosphodiester 
stretching, mainly from nucleic acids[180] 
3 1372 1420 31 72 ●  
COO- symmetric stretching vibration of amino acid side chains 
and fatty acids[167], asymmetric CH3 bending of methyl groups 
of protein[181], C-N stretching, N-H deformation, C-H 
deformation[161] 
3 1424 1476 39 66  11 Methylene deformation in biomolecules[172], CH2 scissoring[168] 
3 1478 1560 47 64 ●  Amide II[183] 
3 1572 1764 68 69 ●  
Amide I[172],[168] band of protein and H-O-H deformation 
vibration of water[184], C=O, C=C uracil, NH2 guanine[161], 
C=O stretching band mode of fatty acid ester[185] 
3 3210 3394 42 68   N-H stretching[153] 
3 3000 3682 32 63 ●  C-H stretching, O-H stretching[152], N-H stretching[153] bands of 
mainly trans-ordered substructures[180] 
Metric type 1, 2 and 3 represent absorbance ratio, area, and center of gravity, respectively. Num. 
and Denom. denote numerator and denominator position, respectively. Histologic class (Hist.) 
and subcellular component (Sub.) indicate the order of metrics by the portion of variance due to 
histologic class effect in between-histologic class model and subcellular component effect in 
within-histologic class model, respectively. Bayes shows the 18 metrics (●) which were used for 
a Bayesian cell-type classifier, and 6 common metrics with the 21 histologic class-dominant 
metrics are designated by *. Array denotes the 19 array-dominant metrics and their order by the 
portion of variance due to array effect. Assignment provides assignment of the spectral bands 
used for 93 metrics. For “Absorption Ratio” metrics, it shows the assignment of the numerator 
band, and the assignment of the denominator band, which does not present among the numerator 
bands, is 1168 cm-1(nucleic acid[186]), 1400cm-1(symmetric stretching vibration of COO- group 
of fatty acids and amino acids[172]), 1460 cm-1(CH2 scissoring [168]), and 1544cm-1(Amide 
II[173]). 
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Appendix B 
Automated Histologic Analysis of 
Prostate Cancer  
 
 
B.1 Validation of Image Registration 
In order to quantitatively validate the accuracy of the method, we conduct experiments using one 
IR classified image and simulated images. We generate the simulated images by transforming the 
given IR classified image with different parameter values: 1) scaling factor s in the range [0.5, 
1.5], 2) rotation angle θ in the range [− , 

], 3) translation (tx, ty) in the range [-50, 50]. For each 
of the three cases, 100 simulated images are generated, and another 100 images are also 
generated by varying all parameters simultaneously. After applying the registration method to 
register the IR classified image with the simulated images, we compared the true parameters with 
the recovered parameters by computing registration error (the absolute difference between 
parameters). As shown in Table S1, the registration method well recovers the true parameters. 
Therefore, we expect the registration method to successfully register the H&E image with the IR 
classified image in the absence of large deformation 
B.2 Epithelium Detection 
In epithelial cells, two types of pixels can be observed – nuclear and cytoplasmic pixels. Our 
strategy to detect epithelial pixels from the H&E stained images is essentially to identify 
cytoplasmic pixels since nuclei can be detected by the above method. The set of observations 
made for epithelial cells above is useful for cytoplasmic pixel detection. In addition to the 
observations, it is noted that the ratio of blue channel intensity to sum of all channel intensity is 
quite high for cytoplasmic pixels. Hence, we compute the value of each pixel as follows: 
B 
1 + ýv + Ù + ý − Ù 
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It emphasizes the pixels that have both higher intensity and relatively higher ratio of blue 
channel and have lower green channel intensity, and such pixels are cytoplasmic pixels in 
general. The segmentation of cytoplasmic areas is performed by finding a threshold value 
iteratively [187]. At iteration i, a threshold value is updated as Ú = 1 ,1 + . where 1 and  
denote the average values of two sets of pixels grouped by the threshold value Ti-1. One set 
contains the pixels whose values are greater than ÚY1 (cytoplasmic areas) and the pixels in the 
other set has the values less than ÚY1 . The thresholding method may not capture all the 
cytoplasmic areas. We grow each cytoplasmic area G© by finding the adjacent pixels within 
AVG"G©& ± 1 STD"G©&. We further indentify and fill small holes inside of each segment to 
include pixels representing epithelial nuclei. The segmented image often contains many salt and 
pepper type noise. To remove them, median filter [188] is applied to the segmented image. As 
did in nucleus detection, adaptive histogram equalization is applied to green channel to deal with 
variability in the stained images prior to epithelium detection. 
B.3 Classification Performance 
The performance of the method is measured by performing 10-fold cross-validation on each 
dataset and validation between datasets. Each experiment is repeated by using different values of 
parameter γ for SVM to examine the effect of the value of the parameter. Regardless of the 
parameter values, we, in general, achieved high classification performance in cross-validation of 
each dataset (Table S2). >0.96 AUCs were achieved for different values of the parameter except 
the cross-validation on Data2 setting γ=10 (~0.91 AUC).  As a classifier is trained on Data1 and 
tested on Data2, the classification results were comparable to the cross-validation results on 
Data2 over different values of the parameter γ (Table S3). Using γ=10, an AUC value of ~0.84 
was achieved which is slightly worse than others (>0.91 AUC). In the opposite experiments, i.e., 
a classifier is trained on Data2 and test on Data1, we obtained the AUCs > 0.83 using γ=1, 0.1, 
0.01, 0.001, and an AUC value of ~0.71 was achieved using γ=10. These classification results 
were substantially worse than the cross-validation results on Data1 (Table S4). However, this 
may not indicate the shortcomings of our method, but reveal the poor generalizability of the 
classifier built on Data2 due to the small number of samples and its imbalance. For the 
experiments without the guidance of IR data, the results, by and large, were consistent in varying 
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the parameter γ, but significant drop in the AUCs was obtained in comparison with the 
classification results with the guidance of IR data. In sum, the classification results were not 
sensitive to the choice of the parameter γ except that the AUCs were dropped when γ=10. 
B.4 Discriminative Features 
At each iteration of cross-validation, the classifier selects the optimal feature set through two-
stage feature selection procedure. We examined whether the selected features and their 
importance are consistent over cross-validation or not. As shown in Figure A.2.1, the maximal 
relevance of 17 feature categories is consistent within each dataset and over all folds of cross-
validation. The features chosen by the classifier are also relatively constant (Figure A.2.2). We 
note that the median number of the optimal feature set is 13 and 7 for Data1 and Datat2, 
respectively. Accordingly, more features have higher frequencies in Figure A.2.2 A.  
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B.5 Figures and Tables 
 
Figure B.1: Importance of 17 feature categories across cross-validation. “Maximal 
relevance” for both datasets (a) Data1 (b) Data2 is consistent over all folds of cross-validation. 
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Figure B.2: Frequency of optimal features across cross-validation. The features in the 
optimal feature set are relatively constant for both datasets (a) Data1 (b) Data2 over all folds of 
cross-validation.  
 
  
125 
 
Table B.1: Registration results with simulated images.  
Varied Parameters Registration Error (s, θ, tx, ty) 
S (0.0109, 0.4735, 0.7705, 0.6874) 
Θ (0.0042, 0.4941, 0.0991, 0.0900) 
tx, ty (0.0028, 0.0662, 0.5068, 0.5734) 
s, θ, tx, ty (0.0097, 3.4416, 0.9626, 0.7353) 
For each case, the average registration error in the recovered parameters is computed over 100 
simulated images. Scaling s, rotation angle θ, and translation (tx, ty) errors are given relative to 
the original image scale, in degrees, and in pixels, respectively. 
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Table B.2: Classification results varying parameter values via cross-validation.  
γ
 
Dataset Feature Extraction 
AUC Sensitivity 
(%) 
Specificity (%) Mf AVG STD AVG STD 
10 
Data1 
IR & HE 0.967 0.0059 
90 88.40 3.74 
9 95 80.77 5.77 
99 62.47 6.51 
HE only 0.945 0.0058 
90 83.21 4.45 
10 95 72.63 5.10 
99 36.78 14.03 
Data2 
IR & HE 0.914 0.0208 
90 63.14 11.26 
4 95 42.43 9.71 
99 31.34 8.92 
HE only 0.735 0.0659 
90 30.18 9.88 
8 95 15.69 8.31 
99 5.04 3.79 
0.1 
Data1 
IR & HE 0.974 0.0048 
90 93.98 2.18 
17.5 95 86.91 3.82 
99 68.08 8.29 
HE only 0.959 0.0043 
90 92.46 1.73 
13 95 82.75 2.92 
99 39.75 5.53 
Data2 
IR & HE 0.963 0.0174 
90 90.48 9.46 
8 95 80.40 15.38 
99 39.59 22.07 
HE only 0.901 0.0073 
90 70.31 9.82 
12 95 33.79 13.92 
99 15.67 12.47 
0.01 
Data1 
IR & HE 0.970 0.0053 
90 93.47 1.66 
13 95 85.50 5.77 
99 51.31 13.05 
HE only 0.955 0.0078 
90 90.76 2.64 
12 95 78.77 3.84 
99 28.77 11.99 
Data2 
IR & HE 0.973 0.0160 
90 93.44 5.57 
9 95 84.44 6.64 
99 49.46 28.54 
HE only 0.894 0.0218 
90 67.57 13.59 
12 95 37.36 15.81 
99 8.87 7.1 
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Table B.2 (cont.) 
γ
 
Dataset Feature Extraction 
AUC Sensitivity 
(%) 
Specificity (%) Mf AVG STD AVG STD 
0.001 
Data1 
IR & HE 0.969 0.0074 
90 92.70 3.04 
12 95 83.47 5.42 
99 51.80 15.65 
HE only 0.954 0.0059 
90 90.62 3.59 
13 95 79.19 3.77 
99 22.41 6.84 
Data2 
IR & HE 0.967 0.0139 
90 92.24 3.46 
10 95 85.07 6.14 
99 40.84 24.25 
HE only 0.879 0.0186 
90 59.01 15.58 
12 95 24.93 13.11 
99 6.73 5.97 
AVG and STD denote average and standard deviation across ten repeats of cross-valdiation. Mf 
is the median size of the feature set obtained by feature selection from training data. Column 
“Feature Extraction” indicates if features were obtained using H&E as well as IR data, or with 
H&E data alone. γ is the parameter of a radial basis kernel for SVM. 
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Table B.3: Classification results on Data2 varying parameter values. 
γ
 
Feature 
Extraction Dataset 
AUC Sensitivity 
(%) 
Specificity (%) Mf AVG STD AVG STD 
10 
IR & HE 
Train 0.999 0.0010 
90 100.00 0.00 
10.5 
95 99.80 0.78 
99 97.90 2.44 
Test 0.849 0.0401 
90 63.60 12.20 
95 46.90 17.55 
99 24.29 6.99 
HE only 
Train 0.999 0.0003 
90 100.00 0.00 
10.5 
95 99.85 0.33 
99 98.84 0.90 
Test 0.846 0.0442 
90 41.76 13.47 
95 28.16 12.89 
99 13.66 9.39 
0.1 
IR & HE 
Train 0.987 0.0004 
90 96.13 0.60 
38 
95 93.77 0.76 
99 86.11 1.39 
Test 0.917 0.0069 
90 70.68 1.99 
95 59.71 3.55 
99 28.29 3.69 
HE only 
Train 0.979 0.0018 
90 97.50 1.56 
14 
95 91.95 2.90 
99 52.41 13.10 
Test 0.896 0.0135 
90 51.90 5.89 
95 32.46 8.99 
99 3.16 1.85 
0.01 
IR & HE 
Train 0.984 0.0031 
90 96.08 1.01 
34 
95 94.36 2.73 
99 80.70 6.82 
Test 0.934 0.0052 
90 76.48 2.62 
95 64.29 3.01 
99 32.57 3.01 
HE only 
Train 0.985 0.0225 
90 97.98 4.44 
15 
95 90.44 14.87 
99 87.23 16.68 
Test 0.893 0.0143 
90 53.13 17.10 
95 25.76 6.63 
99 8.11 5.36 
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Table B.3 (cont.) 
γ
 
Feature 
Extraction Dataset 
AUC Sensitivity 
(%) 
Specificity (%) Mf AVG STD AVG STD 
0.001 
IR & HE 
Train 0.984 0.0032 
90 96.06 0.95 
45 
95 94.00 1.95 
99 78.84 6.16 
Test 0.937 0.0105 
90 78.09 5.62 
95 65.00 6.78 
99 32.57 3.01 
HE only 
Train 0.977 0.0290 
90 93.85 11.40 
13.5 
95 83.45 24.27 
99 81.64 27.07 
Test 0.895 0.0141 
90 58.81 9.71 
95 26.07 10.47 
99 9.33 4.58 
A classifier is trained on Data1 and tested on Data2. AVG and STD denote the average and 
standard deviation. Mf is the median size of the optimal feature set. Column “Feature Extraction” 
indicates if features were obtained using H&E as well as IR data, or with H&E data alone. 
Column “Dataset” indicates if the performance metrics are from training data (Data1) or from 
test data (Data2). γ is the parameter of a radial basis kernel for SVM. 
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Table B.4: Classification results on Data1 varying parameter values. 
γ
 
Feature 
Extraction Dataset 
AUC Sensitivity 
(%) 
Specificity (%) Mf AVG STD AVG STD 
1 
IR & HE 
Train 0.998 0.0007 
90 100.00 0.00 
9 
95 99.71 0.37 
99 95.37 1.75 
Test 0.855 0.0340 
90 50.18 11.52 
95 40.41 9.88 
99 12.33 6.29 
HE only 
Train 0.997 0.0050 
90 100.00 0.00 
8 
95 95.36 7.91 
99 92.79 10.20 
Test 0.804 0.0427 
90 48.58 10.16 
95 37.75 9.96 
99 22.03 9.72 
10 
IR & HE 
Train 0.998 0.0018 
90 99.80 0.63 
7 
95 99.26 1.62 
99 97.08 4.17 
Test 0.719 0.0782 
90 29.41 19.22 
95 21.83 19.42 
99 8.12 11.02 
HE only 
Train 0.998 0.0018 
90 99.80 0.63 
10 
95 99.26 1.62 
99 97.08 4.17 
Test 0.773 0.0534 
90 39.99 10.12 
95 24.71 11.45 
99 12.35 7.74 
0.1 
IR & HE 
Train 0.999 0.0009 
90 100.00 0.00 
11.5 
95 99.71 0.90 
99 97.09 2.56 
Test 0.839 0.0287 
90 39.90 11.64 
95 29.96 9.67 
99 7.94 4.77 
HE only 
Train 0.988 0.0053 
90 100.00 0.00 
9 
95 93.00 5.96 
99 69.00 12.62 
Test 0.768 0.0426 
90 33.06 13.28 
95 20.51 11.69 
99 5.05 4.79 
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Table B.4 (cont.) 
γ
 
Feature 
Extraction Dataset 
AUC Sensitivity 
(%) 
Specificity (%) Mf AVG STD AVG STD 
0.01 
IR & HE 
Train 0.999 0.0011 
90 100.00 0.00 
13 
95 99.64 0.91 
99 97.87 2.79 
Test 0.840 0.0332 
90 39.77 12.94 
95 27.99 10.46 
99 6.02 3.08 
HE only 
Train 0.988 0.0042 
90 100.00 0.00 
11 
95 91.43 8.42 
99 68.74 10.99 
Test 0.773 0.0528 
90 30.62 16.98 
95 15.11 13.58 
99 2.28 2.87 
0.001 
IR & HE 
Train 0.999 0.0011 
90 100.00 0.00 
13 
95 99.64 0.91 
99 97.87 2.79 
Test 0.837 0.0240 
90 39.46 9.58 
95 24.86 5.27 
99 6.59 3.93 
HE only 
Train 0.984 0.0066 
90 97.38 5.56 
11 
95 84.21 11.51 
99 66.57 4.80 
Test 0.769 0.0417 
90 29.31 13.71 
95 14.03 8.25 
99 3.83 5.65 
A classifier is trained on Data2 and tested on Data1. AVG and STD denote the average and 
standard deviation. Mf is the median size of the optimal feature set. Column “Feature Extraction” 
indicates if features were obtained using H&E as well as IR data, or with H&E data alone. 
Column “Dataset” indicates if the performance metrics are from training data (Data2) or from 
test data (Data1). γ is the parameter of a radial basis kernel for SVM. 
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